UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| | | | | |
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2021March 31, 2022
or
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | | 95-3540776 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| |
One Amgen Center Drive | | 91320-1799 |
Thousand Oaks | |
California | |
(Address of principal executive offices) | | (Zip Code) |
(805) 447-1000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common stock, $0.0001 par value | AMGN | The Nasdaq Stock Market LLC |
1.250% Senior Notes due 2022 | AMGN22 | The Nasdaq Stock Market LLC |
2.00% Senior Notes due 2026 | AMGN26 | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | |
Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ |
Smaller reporting company | ☐ | Emerging growth company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
As of October 28, 2021,April 22, 2022, the registrant had 563,265,902534,199,933 shares of common stock, $0.0001 par value, outstanding.
AMGEN INC.
INDEX
| | | | | | | | |
| | Page No. |
| | |
| |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
| |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 6. | | |
| |
| |
Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q—including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.
| | | | | | | | | |
Term | Description | | | | |
| | | | | |
ANDA | Abbreviated New Drug Application | | | | |
AOCI | accumulated other comprehensive income (loss) | | | | |
ASR | accelerated share repurchase | | | | |
BeiGene | BeiGene, Ltd. | | | | |
BiTE® | bispecific T-cell engager | | | | |
COVID-19 | coronavirus disease 2019 | | | | |
EPS | earnings per share | | | | |
ESA | erythropoiesis-stimulating agent | | | | |
EU | European Union | | | | |
FASB | Financial Accounting Standards Board | | | | |
FDA | U.S. Food and Drug Administration | | | | |
Fitch | Fitch Ratings, Inc. | | | | |
GAAP | U.S. generally accepted accounting principles | | | | |
HGRAC | Human Genetic Resources Administration of China | | | | |
IPR&D | in-process research and development | | | | |
IRS | Internal Revenue Service | | | | |
LIBOR | London Interbank Offered Rate | | | | |
mCRPC | metastatic castration-resistant prostate cancer | | | | |
MD&A | management’s discussion and analysis | | | | |
Moody’s | Moody’s Investors Service, Inc. | | | | |
Neumora | Neumora Therapeutics, Inc. | | | | |
NSCLC | non-small cell lung cancer | | | | |
OECD | Organization for Economic Co-operation and Development | | | | |
ORR | objective response rate | | | | |
PFS | progression-free survival | | | | |
PTAB | Patent Trial and Appeal Board | | | | |
R&D | research and development | | | | |
RAR | Revenue Agent Report | | | | |
ROW | rest of world | | | | |
S&P | Standard & Poor’s Financial Services LLC | | | | |
SEC | U.S. Securities and Exchange Commission | | | | |
SOFR | Secured Overnight Financing Rate | | | | |
SG&A | selling, general and administrative | | | | |
Teneobio | Teneobio, Inc. | | | | |
U.S. Treasury | U.S. Department of Treasury | | | | |
UTB | unrecognized tax benefit | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.
| | | | | | | | |
Term | | Description |
Aimovig | | Aimovig® (erenumab-aooe) |
AMGEVITA | | AMGEVITA™ (adalimumab) |
Aranesp | | Aranesp® (darbepoetin alfa) |
BLINCYTO | | BLINCYTO® (blinatumomab) |
ENBREL | | Enbrel® (etanercept) |
EPOGEN | | EPOGEN® (epoetin alfa) |
EVENITY | | EVENITY® (romosozumab-aqqg) |
KANJINTI | | KANJINTI® (trastuzumab-anns) |
KYPROLIS | | KYPROLIS® (carfilzomib) |
LUMAKRAS/LUMYKRAS | | LUMAKRAS® / LUMYKRAS™ (sotorasib) |
MVASI | | MVASI® (bevacizumab-awwb) |
Neulasta | | Neulasta® (pegfilgrastim) |
NEUPOGEN | | NEUPOGEN® (filgrastim) |
Nplate | | Nplate® (romiplostim) |
Onpro | | Onpro® |
Otezla | | Otezla® (apremilast) |
Parsabiv | | Parsabiv® (etelcalcetide) |
Prolia | | Prolia® (denosumab) |
Repatha | | Repatha® (evolocumab) |
Sensipar/Mimpara | | Sensipar®/Mimpara™ (cinacalcet) |
TEZSPIRE | | TEZSPIRE™ (tezepelumab-ekko) |
Vectibix | | Vectibix® (panitumumab) |
XGEVA | | XGEVA® (denosumab) |
PART I — FINANCIAL INFORMATION
| | | | | |
Item 1. | FINANCIAL STATEMENTS |
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)
| | | Three months ended September 30, | | Nine months ended September 30, | | Three months ended March 31, | |
| | 2021 | | 2020 | | 2021 | | 2020 | | 2022 | | 2021 | |
Revenues: | Revenues: | | | | | | | | Revenues: | | | | |
Product sales | Product sales | $ | 6,320 | | | $ | 6,104 | | | $ | 18,026 | | | $ | 17,906 | | Product sales | $ | 5,731 | | | $ | 5,592 | | |
Other revenues | Other revenues | 386 | | | 319 | | | 1,107 | | | 884 | | Other revenues | 507 | | | 309 | | |
Total revenues | Total revenues | 6,706 | | | 6,423 | | | 19,133 | | | 18,790 | | Total revenues | 6,238 | | | 5,901 | | |
| Operating expenses: | Operating expenses: | | Operating expenses: | | |
Cost of sales | Cost of sales | 1,609 | | | 1,561 | | | 4,736 | | | 4,562 | | Cost of sales | 1,561 | | | 1,490 | | |
Research and development | Research and development | 1,422 | | | 1,062 | | | 3,471 | | | 2,978 | | Research and development | 959 | | | 967 | | |
Acquired in-process research and development | — | | | — | | | 1,505 | | | — | | |
| Selling, general and administrative | Selling, general and administrative | 1,305 | | | 1,346 | | | 3,943 | | | 3,957 | | Selling, general and administrative | 1,228 | | | 1,254 | | |
Other | Other | (8) | | | 1 | | | 143 | | | 162 | | Other | (10) | | | 61 | | |
Total operating expenses | Total operating expenses | 4,328 | | | 3,970 | | | 13,798 | | | 11,659 | | Total operating expenses | 3,738 | | | 3,772 | | |
| Operating income | Operating income | 2,378 | | | 2,453 | | | 5,335 | | | 7,131 | | Operating income | 2,500 | | | 2,129 | | |
| Other income (expense): | Other income (expense): | | Other income (expense): | | |
Interest expense, net | Interest expense, net | (296) | | | (302) | | | (862) | | | (944) | | Interest expense, net | (295) | | | (285) | | |
Other income, net | 73 | | | 55 | | | 97 | | | 69 | | |
Other (expense) income, net | | Other (expense) income, net | (530) | | | 13 | | |
| Income before income taxes | Income before income taxes | 2,155 | | | 2,206 | | | 4,570 | | | 6,256 | | Income before income taxes | 1,675 | | | 1,857 | | |
| Provision for income taxes | Provision for income taxes | 271 | | | 185 | | | 576 | | | 607 | | Provision for income taxes | 199 | | | 211 | | |
| Net income | Net income | $ | 1,884 | | | $ | 2,021 | | | $ | 3,994 | | | $ | 5,649 | | Net income | $ | 1,476 | | | $ | 1,646 | | |
| Earnings per share: | Earnings per share: | | Earnings per share: | | |
Basic | Basic | $ | 3.32 | | | $ | 3.45 | | | $ | 6.98 | | | $ | 9.61 | | Basic | $ | 2.69 | | | $ | 2.85 | | |
Diluted | Diluted | $ | 3.31 | | | $ | 3.43 | | | $ | 6.93 | | | $ | 9.54 | | Diluted | $ | 2.68 | | | $ | 2.83 | | |
| Shares used in calculation of earnings per share: | Shares used in calculation of earnings per share: | | Shares used in calculation of earnings per share: | | |
Basic | Basic | 567 | | | 585 | | | 572 | | | 588 | | Basic | 548 | | | 577 | | |
Diluted | Diluted | 570 | | | 589 | | | 576 | | | 592 | | Diluted | 551 | | | 581 | | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | Nine months ended September 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
Net income | $ | 1,884 | | | $ | 2,021 | | | $ | 3,994 | | | $ | 5,649 | |
Other comprehensive income (loss), net of reclassification adjustments and taxes: | | | | | | | |
(Losses) gains on foreign currency translation | (35) | | | 14 | | | (60) | | | (41) | |
Gains (losses) on cash flow hedges | 99 | | | (128) | | | 241 | | | (305) | |
(Losses) gains on available-for-sale securities | (1) | | | 1 | | | (1) | | | (20) | |
Other | (3) | | | (7) | | | (3) | | | (9) | |
Other comprehensive income (loss), net of taxes | 60 | | | (120) | | | 177 | | | (375) | |
Comprehensive income | $ | 1,944 | | | $ | 1,901 | | | $ | 4,171 | | | $ | 5,274 | |
| | | | | | | | | | | | | | | |
| Three months ended March 31, | | |
| 2022 | | 2021 | | | | |
Net income | $ | 1,476 | | | $ | 1,646 | | | | | |
Other comprehensive income, net of reclassification adjustments and taxes: | | | | | | | |
Foreign currency translation | (51) | | | (39) | | | | | |
Cash flow hedges | 84 | | | 190 | | | | | |
| | | | | | | |
Other | — | | | 1 | | | | | |
Other comprehensive income, net of reclassification adjustments and taxes | 33 | | | 152 | | | | | |
Comprehensive income | $ | 1,509 | | | $ | 1,798 | | | | | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)
| | | September 30, 2021 | | December 31, 2020 | | March 31, 2022 | | December 31, 2021 |
| | (Unaudited) | | | | (Unaudited) | | |
ASSETS | ASSETS | ASSETS |
Current assets: | Current assets: | | Current assets: | |
Cash and cash equivalents | Cash and cash equivalents | $ | 11,969 | | | $ | 6,266 | | Cash and cash equivalents | $ | 6,528 | | | $ | 7,989 | |
Marketable securities | Marketable securities | 952 | | | 4,381 | | Marketable securities | 16 | | | 48 | |
Trade receivables, net | Trade receivables, net | 4,765 | | | 4,525 | | Trade receivables, net | 5,077 | | | 4,895 | |
Inventories | Inventories | 4,152 | | | 3,893 | | Inventories | 4,411 | | | 4,086 | |
Other current assets | Other current assets | 2,542 | | | 2,079 | | Other current assets | 2,488 | | | 2,367 | |
Total current assets | Total current assets | 24,380 | | | 21,144 | | Total current assets | 18,520 | | | 19,385 | |
| Property, plant and equipment, net | Property, plant and equipment, net | 4,982 | | | 4,889 | | Property, plant and equipment, net | 5,142 | | | 5,184 | |
Intangible assets, net | Intangible assets, net | 14,659 | | | 16,587 | | Intangible assets, net | 14,567 | | | 15,182 | |
Goodwill | Goodwill | 14,665 | | | 14,689 | | Goodwill | 14,897 | | | 14,890 | |
Other noncurrent assets | Other noncurrent assets | 6,307 | | | 5,639 | | Other noncurrent assets | 6,070 | | | 6,524 | |
Total assets | Total assets | $ | 64,993 | | | $ | 62,948 | | Total assets | $ | 59,196 | | | $ | 61,165 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | LIABILITIES AND STOCKHOLDERS’ EQUITY | LIABILITIES AND STOCKHOLDERS’ EQUITY |
Current liabilities: | Current liabilities: | | Current liabilities: | |
Accounts payable | Accounts payable | $ | 1,171 | | | $ | 1,421 | | Accounts payable | $ | 1,403 | | | $ | 1,366 | |
Accrued liabilities | Accrued liabilities | 9,383 | | | 10,141 | | Accrued liabilities | 10,639 | | | 10,731 | |
Current portion of long-term debt | Current portion of long-term debt | 4,288 | | | 91 | | Current portion of long-term debt | 844 | | | 87 | |
Total current liabilities | Total current liabilities | 14,842 | | | 11,653 | | Total current liabilities | 12,886 | | | 12,184 | |
| Long-term debt | Long-term debt | 33,291 | | | 32,895 | | Long-term debt | 36,010 | | | 33,222 | |
Long-term tax liabilities | Long-term tax liabilities | 6,483 | | | 6,968 | | Long-term tax liabilities | 6,652 | | | 6,594 | |
Other noncurrent liabilities | Other noncurrent liabilities | 2,160 | | | 2,023 | | Other noncurrent liabilities | 2,732 | | | 2,465 | |
| Contingencies and commitments | Contingencies and commitments | 0 | | 0 | Contingencies and commitments | 0 | | 0 |
| Stockholders’ equity: | Stockholders’ equity: | | Stockholders’ equity: | |
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—565.0 shares in 2021 and 578.3 shares in 2020 | 31,989 | | | 31,802 | | |
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.2 shares in 2022 and 558.3 shares in 2021 | | Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.2 shares in 2022 and 558.3 shares in 2021 | 31,247 | | | 32,096 | |
Accumulated deficit | Accumulated deficit | (22,964) | | | (21,408) | | Accumulated deficit | (29,568) | | | (24,600) | |
Accumulated other comprehensive loss | Accumulated other comprehensive loss | (808) | | | (985) | | Accumulated other comprehensive loss | (763) | | | (796) | |
Total stockholders’ equity | Total stockholders’ equity | 8,217 | | | 9,409 | | Total stockholders’ equity | 916 | | | 6,700 | |
Total liabilities and stockholders’ equity | Total liabilities and stockholders’ equity | $ | 64,993 | | | $ | 62,948 | | Total liabilities and stockholders’ equity | $ | 59,196 | | | $ | 61,165 | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)
| | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total |
Balance as of December 31, 2020 | 578.3 | | | $ | 31,802 | | | $ | (21,408) | | | $ | (985) | | | $ | 9,409 | | |
Balance as of December 31, 2021 | | Balance as of December 31, 2021 | 558.3 | | | $ | 32,096 | | | $ | (24,600) | | | $ | (796) | | | $ | 6,700 | |
| Net income | Net income | — | | | — | | | 1,646 | | | — | | | 1,646 | | Net income | — | | | — | | | 1,476 | | | — | | | 1,476 | |
Other comprehensive income, net of taxes | Other comprehensive income, net of taxes | — | | | — | | | — | | | 152 | | | 152 | | Other comprehensive income, net of taxes | — | | | — | | | — | | | 33 | | | 33 | |
Dividends declared on common stock ($1.76 per share) | — | | | — | | | (1,012) | | | — | | | (1,012) | | |
Dividends declared on common stock ($1.94 per share) | | Dividends declared on common stock ($1.94 per share) | — | | | — | | | (1,034) | | | — | | | (1,034) | |
Issuance of common stock in connection with the Company’s equity award programs | Issuance of common stock in connection with the Company’s equity award programs | 0.7 | | | 6 | | | — | | | — | | | 6 | | Issuance of common stock in connection with the Company’s equity award programs | 0.5 | | | 18 | | | — | | | — | | | 18 | |
Stock-based compensation expense | Stock-based compensation expense | — | | | 57 | | | — | | | — | | | 57 | | Stock-based compensation expense | — | | | 78 | | | — | | | — | | | 78 | |
Tax impact related to employee stock-based compensation expense | Tax impact related to employee stock-based compensation expense | — | | | (59) | | | — | | | — | | | (59) | | Tax impact related to employee stock-based compensation expense | — | | | (45) | | | — | | | — | | | (45) | |
Repurchases of common stock | (3.7) | | | — | | | (865) | | | — | | | (865) | | |
Balance as of March 31, 2021 | 575.3 | | | 31,806 | | | (21,639) | | | (833) | | | 9,334 | | |
Repurchases of common stock (Note 10) | | Repurchases of common stock (Note 10) | (24.6) | | | (900) | | | (5,410) | | | — | | | (6,310) | |
Balance as of March 31, 2022 | | Balance as of March 31, 2022 | 534.2 | | | $ | 31,247 | | | $ | (29,568) | | | $ | (763) | | | $ | 916 | |
| Net income | — | | | — | | | 464 | | | — | | | 464 | | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (35) | | | (35) | | |
Issuance of common stock in connection with the Company’s equity award programs | 0.8 | | | 47 | | | — | | | — | | | 47 | | |
Stock-based compensation expense | — | | | 100 | | | — | | | — | | | 100 | | |
Tax impact related to employee stock-based compensation expense | — | | | (76) | | | — | | | — | | | (76) | | |
Repurchases of common stock | (6.5) | | | — | | | (1,592) | | | — | | | (1,592) | | |
Other | — | | | — | | | 5 | | | — | | | 5 | | |
Balance as of June 30, 2021 | 569.6 | | | 31,877 | | | (22,762) | | | (868) | | | 8,247 | | |
| Net income | — | | | — | | | 1,884 | | | — | | | 1,884 | | |
Other comprehensive income, net of taxes | — | | | — | | | — | | | 60 | | | 60 | | |
Dividends declared on common stock ($1.76 per share) | — | | | — | | | (1,017) | | | — | | | (1,017) | | |
Issuance of common stock in connection with the Company’s equity award programs | — | | | 9 | | | — | | | — | | | 9 | | |
Stock-based compensation expense | — | | | 111 | | | — | | | — | | | 111 | | |
Tax impact related to employee stock-based compensation expense | — | | | (8) | | | — | | | — | | | (8) | | |
Repurchases of common stock | (4.6) | | | — | | | (1,069) | | | — | | | (1,069) | | |
| Balance as of September 30, 2021 | 565.0 | | | $ | 31,989 | | | $ | (22,964) | | | $ | (808) | | | $ | 8,217 | | |
|
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(In millions, except per-share data)
(Unaudited)
| | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total |
Balance as of December 31, 2019 | 591.4 | | | $ | 31,531 | | | $ | (21,330) | | | $ | (528) | | | $ | 9,673 | | |
Cumulative effect of changes in accounting principles, net of taxes | — | | | — | | | (2) | | | — | | | (2) | | |
Balance as of December 31, 2020 | | Balance as of December 31, 2020 | 578.3 | | | $ | 31,802 | | | $ | (21,408) | | | $ | (985) | | | $ | 9,409 | |
| Net income | Net income | — | | | — | | | 1,825 | | | — | | | 1,825 | | Net income | — | | | — | | | 1,646 | | | — | | | 1,646 | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (134) | | | (134) | | |
Dividends declared on common stock ($1.60 per share) | — | | | — | | | (938) | | | — | | | (938) | | |
Other comprehensive income, net of taxes | | Other comprehensive income, net of taxes | — | | | — | | | — | | | 152 | | | 152 | |
Dividends declared on common stock ($1.76 per share) | | Dividends declared on common stock ($1.76 per share) | — | | | — | | | (1,012) | | | — | | | (1,012) | |
Issuance of common stock in connection with the Company’s equity award programs | Issuance of common stock in connection with the Company’s equity award programs | 0.9 | | | 10 | | | — | | | — | | | 10 | | Issuance of common stock in connection with the Company’s equity award programs | 0.7 | | | 6 | | | — | | | — | | | 6 | |
Stock-based compensation expense | Stock-based compensation expense | — | | | 52 | | | — | | | — | | | 52 | | Stock-based compensation expense | — | | | 57 | | | — | | | — | | | 57 | |
Tax impact related to employee stock-based compensation expense | Tax impact related to employee stock-based compensation expense | — | | | (68) | | | — | | | — | | | (68) | | Tax impact related to employee stock-based compensation expense | — | | | (59) | | | — | | | — | | | (59) | |
Repurchases of common stock | Repurchases of common stock | (4.3) | | | — | | | (933) | | | — | | | (933) | | Repurchases of common stock | (3.7) | | | — | | | (865) | | | — | | | (865) | |
Balance as of March 31, 2020 | 588.0 | | | 31,525 | | | (21,378) | | | (662) | | | 9,485 | | |
Balance as of March 31, 2021 | | Balance as of March 31, 2021 | 575.3 | | | $ | 31,806 | | | $ | (21,639) | | | $ | (833) | | | $ | 9,334 | |
| Net income | — | | | — | | | 1,803 | | | — | | | 1,803 | | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (121) | | | (121) | | |
| Issuance of common stock in connection with the Company’s equity award programs | 1.0 | | | 65 | | | — | | | — | | | 65 | | |
Stock-based compensation expense | — | | | 101 | | | — | | | — | | | 101 | | |
Tax impact related to employee stock-based compensation expense | — | | | (81) | | | — | | | — | | | (81) | | |
Repurchases of common stock | (2.6) | | | — | | | (591) | | | — | | | (591) | | |
Other | — | | | — | | | (2) | | | — | | | (2) | | |
Balance as of June 30, 2020 | 586.4 | | | 31,610 | | | (20,168) | | | (783) | | | 10,659 | | |
Net income | — | | | — | | | 2,021 | | | — | | | 2,021 | | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (120) | | | (120) | | |
Dividends declared on common stock ($1.60 per share) | — | | | — | | | (952) | | | — | | | (952) | | |
Issuance of common stock in connection with the Company’s equity award programs | 0.1 | | | 5 | | | — | | | — | | | 5 | | |
Stock-based compensation expense | — | | | 109 | | | — | | | — | | | 109 | | |
Tax impact related to employee stock-based compensation expense | — | | | (11) | | | — | | | — | | | (11) | | |
Repurchases of common stock | (3.0) | | | — | | | (752) | | | — | | | (752) | | |
Balance as of September 30, 2020 | 583.5 | | | $ | 31,713 | | | $ | (19,851) | | | $ | (903) | | | $ | 10,959 | | |
|
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
| | | Nine months ended September 30, | | Three months ended March 31, |
| | 2021 | | 2020 | | 2022 | | 2021 |
Cash flows from operating activities: | Cash flows from operating activities: | | | | Cash flows from operating activities: | | | |
Net income | Net income | $ | 3,994 | | | $ | 5,649 | | Net income | $ | 1,476 | | | $ | 1,646 | |
Depreciation, amortization and other | Depreciation, amortization and other | 2,546 | | | 2,728 | | Depreciation, amortization and other | 841 | | | 841 | |
Deferred income taxes | Deferred income taxes | (264) | | | (339) | | Deferred income taxes | (251) | | | (91) | |
Acquired in-process research and development | 1,505 | | | — | | |
| Adjustments for equity method investments | | Adjustments for equity method investments | 305 | | | (85) | |
Other items, net | Other items, net | 187 | | | 270 | | Other items, net | 240 | | | 164 | |
Changes in operating assets and liabilities, net of acquisitions: | Changes in operating assets and liabilities, net of acquisitions: | | Changes in operating assets and liabilities, net of acquisitions: | |
Trade receivables, net | Trade receivables, net | (269) | | | (31) | | Trade receivables, net | (195) | | | 91 | |
Inventories | Inventories | (215) | | | (316) | | Inventories | (230) | | | (126) | |
Other assets | Other assets | (373) | | | 64 | | Other assets | (43) | | | (146) | |
Accounts payable | Accounts payable | (260) | | | (202) | | Accounts payable | 42 | | | (29) | |
Accrued income taxes, net | Accrued income taxes, net | (719) | | | (301) | | Accrued income taxes, net | 318 | | | 52 | |
Long-term tax liabilities | Long-term tax liabilities | 102 | | | 110 | | Long-term tax liabilities | 57 | | | 69 | |
Other liabilities | Other liabilities | 219 | | | 712 | | Other liabilities | (396) | | | (282) | |
Net cash provided by operating activities | Net cash provided by operating activities | 6,453 | | | 8,344 | | Net cash provided by operating activities | 2,164 | | | 2,104 | |
Cash flows from investing activities: | Cash flows from investing activities: | | | | Cash flows from investing activities: | | | |
Cash paid for acquisitions, net of cash acquired | (1,639) | | | — | | |
| Purchases of marketable securities | Purchases of marketable securities | (8,901) | | | (5,329) | | Purchases of marketable securities | — | | | (7,597) | |
Proceeds from sales of marketable securities | Proceeds from sales of marketable securities | 4,403 | | | 2,597 | | Proceeds from sales of marketable securities | — | | | 3,999 | |
Proceeds from maturities of marketable securities | Proceeds from maturities of marketable securities | 7,927 | | | 2,338 | | Proceeds from maturities of marketable securities | 32 | | | 3,524 | |
| Purchases of property, plant and equipment | Purchases of property, plant and equipment | (593) | | | (435) | | Purchases of property, plant and equipment | (190) | | | (166) | |
Purchases of equity method investments | (154) | | | (3,154) | | |
| Other | Other | (80) | | | (34) | | Other | 47 | | | (79) | |
Net cash provided by (used in) investing activities | 963 | | | (4,017) | | |
Net cash used in investing activities | | Net cash used in investing activities | (111) | | | (319) | |
Cash flows from financing activities: | Cash flows from financing activities: | | | | Cash flows from financing activities: | | | |
Net proceeds from issuance of debt | Net proceeds from issuance of debt | 4,946 | | | 8,914 | | Net proceeds from issuance of debt | 3,952 | | | — | |
Repayment of debt | — | | | (5,000) | | |
| Repurchases of common stock | (3,532) | | | (2,281) | | |
| Repurchases of common stock (Note 10) | | Repurchases of common stock (Note 10) | (6,360) | | | (871) | |
Dividends paid | Dividends paid | (3,023) | | | (2,823) | | Dividends paid | (1,080) | | | (1,016) | |
| Other | Other | (104) | | | (87) | | Other | (26) | | | (52) | |
Net cash used in financing activities | Net cash used in financing activities | (1,713) | | | (1,277) | | Net cash used in financing activities | (3,514) | | | (1,939) | |
Increase in cash and cash equivalents | 5,703 | | | 3,050 | | |
Decrease in cash and cash equivalents | | Decrease in cash and cash equivalents | (1,461) | | | (154) | |
Cash and cash equivalents at beginning of period | Cash and cash equivalents at beginning of period | 6,266 | | | 6,037 | | Cash and cash equivalents at beginning of period | 7,989 | | | 6,266 | |
Cash and cash equivalents at end of period | Cash and cash equivalents at end of period | $ | 11,969 | | | $ | 9,087 | | Cash and cash equivalents at end of period | $ | 6,528 | | | $ | 6,112 | |
See accompanying notes.
AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2021March 31, 2022
(Unaudited)
1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in 1 business segment: human therapeutics.
Basis of presentation
The financial information for the three and nine months ended September 30,March 31, 2022 and 2021, and 2020, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities.entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $9.2$8.9 billion and $9.0$8.8 billion as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively.
Recent accounting pronouncements
In March 2020, the Financial Accounting Standards Board (FASB)FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the London Interbank Offered Rate (LIBOR)LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand onthat expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impacts thatdo not expect the two standards willto have a material impact on our condensed consolidated financial statements.
In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.
2. Acquisitions
Teneobio, Inc.
On April 16,October 19, 2021, Amgen completed its acquisitionwe acquired all of Five Prime Therapeutics, Inc. (Five Prime) for total considerationthe outstanding stock of $1.6 billion, netTeneobio, a privately held, clinical-stage biotechnology company developing a new class of cash acquired.biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The purchase price was funded with cash on hand. This transaction, which was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrateda business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and BiTE® platform and will enable significant acceleration and efficiency in the intellectual property rightsdiscovery and development of bemarituzumab,new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime’swholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing afteron the acquisition date.
Measurement period adjustments for the three months ended March 31, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22 million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen’s results of operations for the three months ended March 31, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):
| | | | | | | | |
| | Amounts |
Cash purchase price | | $ | 993 | |
Contingent consideration | | 299 | |
Total consideration | | $ | 1,292 | |
| | |
Cash and cash equivalents | | $ | 100 | |
IPR&D | | 991 | |
Finite-lived intangible asset – R&D technology rights | | 115 | |
Finite-lived intangible assets – licensing rights | | 41 | |
Goodwill | | 273 | |
Other assets, net | | 16 | |
Deferred tax liability | | (244) | |
Total assets acquired, net | | $ | 1,292 | |
The consideration for this transaction comprised (i) an upfront cash payment of $993 million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pre-tax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of March 31, 2022.
The estimated fair values of acquired IPR&D assets totaled $991 million, of which $784 million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of mCRPC, and the balance relates to four separate preclinical oncology programs. The R&D technology rights of $115 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies and will be amortized over 10 years using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.
A deferred tax liability of $244 million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.
The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.
Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.
We allocated the consideration to acquire Five Prime to: the bemarituzumab in-process research and development (IPR&D) program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The acquired IPR&D expense was not tax deductible.
3. Revenues
We operate in 1 business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of rest-of-world (ROW)ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, |
| | 2021 | | 2020 |
| | U.S. | | ROW | | Total | | U.S. | | ROW | | Total |
Enbrel® (etanercept) | | $ | 1,263 | | | $ | 26 | | | $ | 1,289 | | | $ | 1,289 | | | $ | 36 | | | $ | 1,325 | |
Prolia® (denosumab) | | 530 | | | 273 | | | 803 | | | 478 | | | 223 | | | 701 | |
Otezla® (apremilast) | | 495 | | | 114 | | | 609 | | | 439 | | | 99 | | | 538 | |
XGEVA® (denosumab) | | 372 | | | 145 | | | 517 | | | 363 | | | 118 | | | 481 | |
Neulasta® (pegfilgrastim) | | 360 | | | 55 | | | 415 | | | 484 | | | 71 | | | 555 | |
Aranesp® (darbepoetin alfa) | | 149 | | | 247 | | | 396 | | | 158 | | | 226 | | | 384 | |
Repatha® (evolocumab) | | 139 | | | 133 | | | 272 | | | 92 | | | 113 | | | 205 | |
KYPROLIS® (carfilzomib) | | 198 | | | 95 | | | 293 | | | 173 | | | 87 | | | 260 | |
Other products | | 1,052 | | | 674 | | | 1,726 | | | 1,142 | | | 513 | | | 1,655 | |
Total product sales(1) | | $ | 4,558 | | | $ | 1,762 | | | 6,320 | | | $ | 4,618 | | | $ | 1,486 | | | 6,104 | |
Other revenues | | | | | | 386 | | | | | | | 319 | |
Total revenues | | | | | | $ | 6,706 | | | | | | | $ | 6,423 | |
| | | | | | | | | | | | |
| | Nine months ended September 30, |
| | 2021 | | 2020 |
| | U.S. | | ROW | | Total | | U.S. | | ROW | | Total |
ENBREL | | $ | 3,270 | | | $ | 87 | | | $ | 3,357 | | | $ | 3,619 | | | $ | 105 | | | $ | 3,724 | |
Prolia® | | 1,569 | | | 806 | | | 2,375 | | | 1,341 | | | 673 | | | 2,014 | |
Otezla® | | 1,284 | | | 335 | | | 1,619 | | | 1,280 | | | 298 | | | 1,578 | |
XGEVA® | | 1,061 | | | 412 | | | 1,473 | | | 1,036 | | | 361 | | | 1,397 | |
Neulasta® | | 1,215 | | | 168 | | | 1,383 | | | 1,538 | | | 219 | | | 1,757 | |
Aranesp® | | 409 | | | 709 | | | 1,118 | | | 489 | | | 704 | | | 1,193 | |
Repatha® | | 421 | | | 423 | | | 844 | | | 331 | | | 303 | | | 634 | |
KYPROLIS® | | 547 | | | 277 | | | 824 | | | 527 | | | 266 | | | 793 | |
Other products | | 3,059 | | | 1,974 | | | 5,033 | | | 3,164 | | | 1,652 | | | 4,816 | |
Total product sales(1) | | $ | 12,835 | | | $ | 5,191 | | | 18,026 | | | $ | 13,325 | | | $ | 4,581 | | | 17,906 | |
Other revenues | | | | | | 1,107 | | | | | | | 884 | |
Total revenues | | | | | | $ | 19,133 | | | | | | | $ | 18,790 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three months ended March 31, |
| | 2022 | | 2021 |
| | U.S. | | ROW | | Total | | U.S. | | ROW | | Total |
Enbrel | | $ | 843 | | | $ | 19 | | | $ | 862 | | | $ | 894 | | | $ | 30 | | | $ | 924 | |
Prolia | | 582 | | | 270 | | | 852 | | | 501 | | | 257 | | | 758 | |
XGEVA | | 368 | | | 134 | | | 502 | | | 334 | | | 134 | | | 468 | |
Otezla | | 350 | | | 101 | | | 451 | | | 366 | | | 110 | | | 476 | |
Aranesp | | 137 | | | 221 | | | 358 | | | 125 | | | 230 | | | 355 | |
Neulasta | | 304 | | | 44 | | | 348 | | | 421 | | | 61 | | | 482 | |
Repatha | | 165 | | | 164 | | | 329 | | | 139 | | | 147 | | | 286 | |
KYPROLIS | | 196 | | | 91 | | | 287 | | | 159 | | | 92 | | | 251 | |
Nplate | | 156 | | | 110 | | | 266 | | | 112 | | | 115 | | | 227 | |
Other products | | 936 | | | 540 | | | 1,476 | | | 852 | | | 513 | | | 1,365 | |
Total product sales(1) | | $ | 4,037 | | | $ | 1,694 | | | 5,731 | | | $ | 3,903 | | | $ | 1,689 | | | 5,592 | |
Other revenues | | | | | | 507 | | | | | | | 309 | |
Total revenues | | | | | | $ | 6,238 | | | | | | | $ | 5,901 | |
| | | | | | | | | | | | |
| | |
| | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
____________
(1) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2021March 31, 2022 and 2020.2021.
4. Income taxes
The effective tax raterates for the three and nine months ended September 30,March 31, 2022 and 2021, was 12.6% for both periods, compared with rates of 8.4%were 11.9% and 9.7%11.4%, respectively, for the corresponding periods of the prior year.respectively.
The increase in our effective tax rate for the three and nine months ended September 30, 2021,March 31, 2022, was primarily due to the non-deductible IPR&D expense arising from the acquisition of Five Prime and priorcurrent year favorablenet unfavorable items partiallycompared to last year, offset by a changechanges in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are subject to a tax incentive grant through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.
The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, in 2022 the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arisecan and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities (including the IRS) are becoming more aggressive and are particularly focused on such matters.
In 2017, we received a Revenue Agent Report (RAR)an RAR and a modified RAR from the Internal Revenue Service (IRS)IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. As previously reported, we were unable to reach resolution with the IRS appeals office.office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for 2010, 2011 and 2012 that we received in May and July 2021. The duplicate Notices2021, which seek to increase our U.S. taxable income for 2010-2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for 2010-2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In any event, we firmly believe that the IRS’s positions in the Notices are without merit, and we will vigorously contest the Notices through the judicial process.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreedisagreed with the proposed adjustments and calculations and have been pursuingpursued resolution with the IRS administrative appeals office. Asoffice but were unable to reach resolution. In April 2022, we received a consequenceNotice that seeks to increase our U.S. taxable income for 2013-2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for 2013-2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.
We firmly believe that the IRS positions set forth in the 2010-2012 and 2013-2015 Notices are without merit. We are contesting the 2010-2012 Notices through the judicial process, and we expect to file a Petition in the U.S. Tax Court to contest the 2013-2015 Notice through the judicial process. We will seek consolidation of the two periods into one case in Tax Court litigation for the 2010-2012 period, the IRS administrative appeals office recently informed us that it does not plan to engage in discussions at this time regarding the allocation of profits between our entities in the United States and the U.S. territory of Puerto Rico for the 2013-2015 period. Court.
We are also currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination2018 and by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.
We are no longer subject to U.S. federal income tax examinations for the years ended on or before December 31, 2009.
See Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Income Taxes for further discussion and Part II, Item 1A, Risk Factors—The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
During the three and nine months ended September 30, 2021,March 31, 2022, the gross amounts of our unrecognized tax benefits (UTBs)UTBs increased $70$45 million, and $180 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of September 30, 2021,March 31, 2022, if recognized, would affect our effective tax rate.
5. Earnings per share
The computation of basic earnings per share (EPS)EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
| | | Three months ended September 30, | | Nine months ended September 30, | | Three months ended March 31, | |
| | 2021 | | 2020 | | 2021 | | 2020 | | 2022 | | 2021 | |
Income (Numerator): | Income (Numerator): | | | | | | | | Income (Numerator): | | | | |
Net income for basic and diluted EPS | Net income for basic and diluted EPS | $ | 1,884 | | | $ | 2,021 | | | $ | 3,994 | | | $ | 5,649 | | Net income for basic and diluted EPS | $ | 1,476 | | | $ | 1,646 | | |
| Shares (Denominator): | Shares (Denominator): | | Shares (Denominator): | | |
Weighted-average shares for basic EPS | Weighted-average shares for basic EPS | 567 | | | 585 | | | 572 | | | 588 | | Weighted-average shares for basic EPS | 548 | | | 577 | | |
Effect of dilutive securities | Effect of dilutive securities | 3 | | | 4 | | | 4 | | | 4 | | Effect of dilutive securities | 3 | | | 4 | | |
Weighted-average shares for diluted EPS | Weighted-average shares for diluted EPS | 570 | | | 589 | | | 576 | | | 592 | | Weighted-average shares for diluted EPS | 551 | | | 581 | | |
| Basic EPS | Basic EPS | $ | 3.32 | | | $ | 3.45 | | | $ | 6.98 | | | $ | 9.61 | | Basic EPS | $ | 2.69 | | | $ | 2.85 | | |
Diluted EPS | Diluted EPS | $ | 3.31 | | | $ | 3.43 | | | $ | 6.93 | | | $ | 9.54 | | Diluted EPS | $ | 2.68 | | | $ | 2.83 | | |
For the three and nine months ended September 30,March 31, 2022 and 2021, and 2020, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.
6. Collaborations
On July 30, 2021, we closed our collaboration and licensing agreement with Kyowa Kirin Co., Ltd. (KKC) to jointly develop and commercialize an anti-OX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential in other autoimmune diseases.
Under the terms of the agreement, we will lead the global development, manufacturing and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia.
We made an upfront payment of $400 million to KKC that was recognized in Research and development (R&D) expense in the third quarter of 2021. Amgen and KKC will share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside of the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan.
6. Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
| Types of securities as of September 30, 2021 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values | |
Types of securities as of March 31, 2022 | | Types of securities as of March 31, 2022 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | U.S. Treasury notes | | $ | 51 | | | $ | — | | | $ | — | | | $ | 51 | | U.S. Treasury notes | | $ | 16 | | | $ | — | | | $ | — | | | $ | 16 | |
U.S. Treasury bills | U.S. Treasury bills | | 3,900 | | | — | | | — | | | 3,900 | | U.S. Treasury bills | | — | | | — | | | — | | | — | |
| Money market mutual funds | Money market mutual funds | | 8,323 | | | — | | | — | | | 8,323 | | Money market mutual funds | | 5,837 | | | — | | | — | | | 5,837 | |
Other short-term interest-bearing securities | Other short-term interest-bearing securities | | 1 | | | — | | | — | | | 1 | | Other short-term interest-bearing securities | | — | | | — | | | — | | | — | |
| Total interest-bearing securities | Total interest-bearing securities | | $ | 12,275 | | | $ | — | | | $ | — | | | $ | 12,275 | | Total interest-bearing securities | | $ | 5,853 | | | $ | — | | | $ | — | | | $ | 5,853 | |
| Types of securities as of December 31, 2020 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values | |
Types of securities as of December 31, 2021 | | Types of securities as of December 31, 2021 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | U.S. Treasury notes | | $ | 129 | | | $ | 1 | | | $ | — | | | $ | 130 | | U.S. Treasury notes | | $ | 47 | | | $ | — | | | $ | — | | | $ | 47 | |
U.S. Treasury bills | U.S. Treasury bills | | 4,948 | | | — | | | — | | | 4,948 | | U.S. Treasury bills | | 1,400 | | | — | | | — | | | 1,400 | |
| Money market mutual funds | Money market mutual funds | | 4,765 | | | — | | | — | | | 4,765 | | Money market mutual funds | | 5,856 | | | — | | | — | | | 5,856 | |
Other short-term interest-bearing securities | Other short-term interest-bearing securities | | 2 | | | — | | | — | | | 2 | | Other short-term interest-bearing securities | | 1 | | | — | | | — | | | 1 | |
Total interest-bearing securities | Total interest-bearing securities | | $ | 9,844 | | | $ | 1 | | | $ | — | | | $ | 9,845 | | Total interest-bearing securities | | $ | 7,304 | | | $ | — | | | $ | — | | | $ | 7,304 | |
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
| Condensed Consolidated Balance Sheets locations | Condensed Consolidated Balance Sheets locations | | September 30, 2021 | | December 31, 2020 | Condensed Consolidated Balance Sheets locations | | March 31, 2022 | | December 31, 2021 |
Cash and cash equivalents | Cash and cash equivalents | | $ | 11,323 | | | $ | 5,464 | | Cash and cash equivalents | | $ | 5,837 | | | $ | 7,256 | |
Marketable securities | Marketable securities | | 952 | | | 4,381 | | Marketable securities | | 16 | | | 48 | |
Total interest-bearing securities | Total interest-bearing securities | | $ | 12,275 | | | $ | 9,845 | | Total interest-bearing securities | | $ | 5,853 | | | $ | 7,304 | |
Cash and cash equivalents in the above table excludes bank account cash of $646$691 million and $802$733 million as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively.
The fair values of available-for-sale investments by contractual maturity were as follows (in millions):
| Contractual maturities | Contractual maturities | | September 30, 2021 | | December 31, 2020 | Contractual maturities | | March 31, 2022 | | December 31, 2021 |
Maturing in one year or less | Maturing in one year or less | | $ | 12,275 | | | $ | 9,795 | | Maturing in one year or less | | $ | 5,853 | | | $ | 7,304 | |
Maturing after one year through three years | | — | | | 50 | | |
| | Total available-for-sale investments | Total available-for-sale investments | | $ | 12,275 | | | $ | 9,845 | | Total available-for-sale investments | | $ | 5,853 | | | $ | 7,304 | |
For the three and nine months ended September 30,March 31, 2022 and 2021, and 2020, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Equity securities
We held investments in equity securities with readily determinable fair values (publicly traded securities) of $608$473 million and $477$611 million as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. For the three months ended September 30,March 31, 2022 and 2021, and 2020, net unrealized gainslosses on publicly traded securities were $135$170 million and $60 million, respectively. For the nine months ended September 30, 2021 and 2020, net unrealized gains on publicly traded securities were $104 million and $65$56 million, respectively. Realized gains and losses on sales of publicly traded securities for the three and nine months ended September 30,March 31, 2022 and 2021, and 2020 were not material.
We held investments of $255$261 million and $203$262 million in equity securities without readily determinable fair values as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. For the three months ended September 30,March 31, 2022 and 2021, and 2020, gains due to upward adjustments on these securities were $94 million and $12 million, respectively. For the nine months ended September 30, 2021 and 2020, gains due to upward adjustments on these securities were $129 million and $20 million, respectively. Downwarddownward adjustments on these securities were not material. Adjustments were based on observable price transactions.
Equity method investments
BeiGene, Ltd.
As of September 30,March 31, 2022 and December 31, 2021, we had an ownership interest of approximately 20.3%18.4% in BeiGene, Ltd. (BeiGene), which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in Other (expense) income, net, in the Condensed Consolidated Statements of Income one quarter in arrears, which began in the second quarter of 2020.arrears.
During the three and nine months ended September 30,March 31, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net losslosses of $98$108 million and $181$97 million, respectively, and amortization of the basis difference of $44$47 million and $128$42 million, respectively. During the threeAs of March 31, 2022 and nine months ended September 30,December 31, 2021, the carrying value increased by $18 million and $56 million, respectively, from the impact of BeiGene ownership transactions. In addition, during the three and nine months ended September 30, 2021, we increased the carrying value by $50 million as a result of our purchase of additional shares directly from BeiGene. As of September 30, 2021, the carrying value and fair valuevalues of our investment in BeiGene totaled $2.7$2.6 billion and $6.9$2.8 billion, respectively, and the fair values of the investment totaled $3.6 billion and $5.1 billion, respectively. As of September 30, 2021,March 31, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.
Neumora Therapeutics, Inc.
On September 30, 2021, we acquired approximately 25.9% ownership interest in Neumora, Therapeutics, Inc. (Neumora), a privately held company, for $257 million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100 million cash payment and $157 million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of March 31, 2022 and December 31, 2021, our ownership interest in Neumora was 25.8% and 25.9%, respectively, and the fair values of our investment were $170 million and $220 million, respectively. Accordingly, during the three months ended March 31, 2022, we recognized a loss of $50 million for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.
Limited partnerships
We held limited partnership investments of $556$403 million and $496$573 million as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2021,March 31, 2022, unfunded additional commitments to be made for these investments during the next several years were not material. For$182 million. During the three months ended September 30,March 31, 2022 and 2021, and 2020,we recognized net unrealized gains and losses on our limited partnership investments were a net loss of $43$160 million and a net gaingains of $63$208 million, respectively. Forrespectively, in Other (expense) income, net in the nine months ended September 30, 2021 and 2020, net unrealized gains from our limited partnership investments were $122 million and $73 million, respectively.Condensed Consolidated Statements of Income on these investments.
7. Inventories
Inventories consisted of the following (in millions):
| | | September 30, 2021 | | December 31, 2020 | | March 31, 2022 | | December 31, 2021 |
Raw materials | Raw materials | $ | 667 | | | $ | 486 | | Raw materials | $ | 750 | | | $ | 647 | |
Work in process | Work in process | 2,313 | | | 2,437 | | Work in process | 2,582 | | | 2,367 | |
Finished goods | Finished goods | 1,172 | | | 970 | | Finished goods | 1,079 | | | 1,072 | |
Total inventories | Total inventories | $ | 4,152 | | | $ | 3,893 | | Total inventories | $ | 4,411 | | | $ | 4,086 | |
9.8. Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
| | | | | |
| NineThree months ended
September 30, 2021March 31, 2022 |
Beginning balance | $ | 14,68914,890 | |
Goodwill resulting from acquisition of a business(1) | 22 | |
Currency translation adjustment | (24)(15) | |
Ending balance | $ | 14,66514,897 | |
____________
(1) Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio (see Note 2, Acquisitions).
Other intangible assets
Other intangible assets consisted of the following (in millions):
| | | September 30, 2021 | | December 31, 2020 | | March 31, 2022 | | December 31, 2021 |
| | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net | | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net | | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net | | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net |
Finite-lived intangible assets: | Finite-lived intangible assets: | | | | | | | | | | | | Finite-lived intangible assets: | | | | | | | | | | | |
Developed-product-technology rights | Developed-product-technology rights | $ | 25,575 | | | $ | (12,222) | | | $ | 13,353 | | | $ | 25,591 | | | $ | (10,564) | | | $ | 15,027 | | Developed-product-technology rights | $ | 25,550 | | | $ | (13,316) | | | $ | 12,234 | | | $ | 25,561 | | | $ | (12,769) | | | $ | 12,792 | |
Licensing rights | Licensing rights | 3,766 | | | (2,931) | | | 835 | | | 3,743 | | | (2,791) | | | 952 | | Licensing rights | 3,864 | | | (3,013) | | | 851 | | | 3,807 | | | (2,973) | | | 834 | |
Marketing-related rights | Marketing-related rights | 1,362 | | | (1,099) | | | 263 | | | 1,367 | | | (1,041) | | | 326 | | Marketing-related rights | 1,350 | | | (1,129) | | | 221 | | | 1,354 | | | (1,112) | | | 242 | |
Research and development technology rights | Research and development technology rights | 1,298 | | | (1,120) | | | 178 | | | 1,317 | | | (1,065) | | | 252 | | Research and development technology rights | 1,386 | | | (1,146) | | | 240 | | | 1,377 | | | (1,133) | | | 244 | |
Total finite-lived intangible assets | Total finite-lived intangible assets | 32,001 | | | (17,372) | | | 14,629 | | | 32,018 | | | (15,461) | | | 16,557 | | Total finite-lived intangible assets | 32,150 | | | (18,604) | | | 13,546 | | | 32,099 | | | (17,987) | | | 14,112 | |
Indefinite-lived intangible assets: | Indefinite-lived intangible assets: | | Indefinite-lived intangible assets: | |
In-process research and development | In-process research and development | 30 | | | — | | | 30 | | | 30 | | | — | | | 30 | | In-process research and development | 1,021 | | | — | | | 1,021 | | | 1,070 | | | — | | | 1,070 | |
Total other intangible assets | Total other intangible assets | $ | 32,031 | | | $ | (17,372) | | | $ | 14,659 | | | $ | 32,048 | | | $ | (15,461) | | | $ | 16,587 | | Total other intangible assets | $ | 33,171 | | | $ | (18,604) | | | $ | 14,567 | | | $ | 33,169 | | | $ | (17,987) | | | $ | 15,182 | |
Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses.
IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended September 30,March 31, 2022 and 2021, and 2020, we recognized amortization associated with our finite-lived intangible assets of $642$637 million and $708$654 million, respectively. During the nine months ended September 30, 2021 and 2020, we recognized amortization associated with our finite-lived intangible assets of $1.9 billion and $2.1 billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining threenine months ending December 31, 2021,2022, and the years ending December 31, 2022, 2023, 2024, 2025, 2026 and 2026,2027, are $0.6$1.9 billion, $2.5 billion, $2.5 billion, $2.4 billion, $2.4 billion, $2.2$1.7 billion and $1.8 billion, respectively.
9. Financing arrangements
Our borrowings consisted of the following (in millions):
| | | September 30, 2021 | | December 31, 2020 | | March 31, 2022 | | December 31, 2021 |
1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) | $ | 1,448 | | | $ | 1,527 | | |
2.70% notes due 2022 (2.70% 2022 Notes) | 500 | | | 500 | | |
2.65% notes due 2022 (2.65% 2022 Notes) | 1,500 | | | 1,500 | | |
3.625% notes due 2022 (3.625% 2022 Notes) | 750 | | | 750 | | |
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | 751 | | | 791 | | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | $ | 759 | | | $ | 767 | |
2.25% notes due 2023 (2.25% 2023 Notes) | 2.25% notes due 2023 (2.25% 2023 Notes) | 750 | | | 750 | | 2.25% notes due 2023 (2.25% 2023 Notes) | 750 | | | 750 | |
3.625% notes due 2024 (3.625% 2024 Notes) | 3.625% notes due 2024 (3.625% 2024 Notes) | 1,400 | | | 1,400 | | 3.625% notes due 2024 (3.625% 2024 Notes) | 1,400 | | | 1,400 | |
1.90% notes due 2025 (1.90% 2025 Notes) | 1.90% notes due 2025 (1.90% 2025 Notes) | 500 | | | 500 | | 1.90% notes due 2025 (1.90% 2025 Notes) | 500 | | | 500 | |
3.125% notes due 2025 (3.125% 2025 Notes) | 3.125% notes due 2025 (3.125% 2025 Notes) | 1,000 | | | 1,000 | | 3.125% notes due 2025 (3.125% 2025 Notes) | 1,000 | | | 1,000 | |
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | 869 | | | 916 | | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | 830 | | | 853 | |
2.60% notes due 2026 (2.60% 2026 Notes) | 2.60% notes due 2026 (2.60% 2026 Notes) | 1,250 | | | 1,250 | | 2.60% notes due 2026 (2.60% 2026 Notes) | 1,250 | | | 1,250 | |
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | 640 | | | 649 | | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | 624 | | | 643 | |
2.20% notes due 2027 (2.20% 2027 Notes) | 2.20% notes due 2027 (2.20% 2027 Notes) | 1,750 | | | 1,750 | | 2.20% notes due 2027 (2.20% 2027 Notes) | 1,750 | | | 1,750 | |
3.20% notes due 2027 (3.20% 2027 Notes) | 3.20% notes due 2027 (3.20% 2027 Notes) | 1,000 | | | 1,000 | | 3.20% notes due 2027 (3.20% 2027 Notes) | 1,000 | | | 1,000 | |
1.65% note due 2028 (1.65% 2028 Notes) | 1,250 | | | — | | |
1.65% notes due 2028 (1.65% 2028 Notes) | | 1.65% notes due 2028 (1.65% 2028 Notes) | 1,250 | | | 1,250 | |
3.00% notes due 2029 (3.00% 2029 Notes) | | 3.00% notes due 2029 (3.00% 2029 Notes) | 750 | | | — | |
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | 943 | | | 957 | | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | 920 | | | 947 | |
2.45% notes due 2030 (2.45% 2030 Notes) | 2.45% notes due 2030 (2.45% 2030 Notes) | 1,250 | | | 1,250 | | 2.45% notes due 2030 (2.45% 2030 Notes) | 1,250 | | | 1,250 | |
2.30% notes due 2031 (2.30% 2031 Notes) | 2.30% notes due 2031 (2.30% 2031 Notes) | 1,250 | | | 1,250 | | 2.30% notes due 2031 (2.30% 2031 Notes) | 1,250 | | | 1,250 | |
2.00% notes due 2032 (2.00% 2032 Notes) | 2.00% notes due 2032 (2.00% 2032 Notes) | 1,250 | | | — | | 2.00% notes due 2032 (2.00% 2032 Notes) | 1,250 | | | 1,250 | |
3.35% notes due 2032 (3.35% 2032 Notes) | | 3.35% notes due 2032 (3.35% 2032 Notes) | 1,000 | | | — | |
6.375% notes due 2037 (6.375% 2037 Notes) | 6.375% notes due 2037 (6.375% 2037 Notes) | 478 | | | 478 | | 6.375% notes due 2037 (6.375% 2037 Notes) | 478 | | | 478 | |
6.90% notes due 2038 (6.90% 2038 Notes) | 6.90% notes due 2038 (6.90% 2038 Notes) | 254 | | | 254 | | 6.90% notes due 2038 (6.90% 2038 Notes) | 254 | | | 254 | |
6.40% notes due 2039 (6.40% 2039 Notes) | 6.40% notes due 2039 (6.40% 2039 Notes) | 333 | | | 333 | | 6.40% notes due 2039 (6.40% 2039 Notes) | 333 | | | 333 | |
3.15% notes due 2040 (3.15% 2040 Notes) | 3.15% notes due 2040 (3.15% 2040 Notes) | 2,000 | | | 2,000 | | 3.15% notes due 2040 (3.15% 2040 Notes) | 2,000 | | | 2,000 | |
5.75% notes due 2040 (5.75% 2040 Notes) | 5.75% notes due 2040 (5.75% 2040 Notes) | 373 | | | 373 | | 5.75% notes due 2040 (5.75% 2040 Notes) | 373 | | | 373 | |
2.80% note due 2041 (2.80% 2041 Notes) | 1,150 | | | — | | |
2.80% notes due 2041 (2.80% 2041 Notes) | | 2.80% notes due 2041 (2.80% 2041 Notes) | 1,150 | | | 1,150 | |
4.95% notes due 2041 (4.95% 2041 Notes) | 4.95% notes due 2041 (4.95% 2041 Notes) | 600 | | | 600 | | 4.95% notes due 2041 (4.95% 2041 Notes) | 600 | | | 600 | |
5.15% notes due 2041 (5.15% 2041 Notes) | 5.15% notes due 2041 (5.15% 2041 Notes) | 729 | | | 729 | | 5.15% notes due 2041 (5.15% 2041 Notes) | 729 | | | 729 | |
5.65% notes due 2042 (5.65% 2042 Notes) | 5.65% notes due 2042 (5.65% 2042 Notes) | 415 | | | 415 | | 5.65% notes due 2042 (5.65% 2042 Notes) | 415 | | | 415 | |
5.375% notes due 2043 (5.375% 2043 Notes) | 5.375% notes due 2043 (5.375% 2043 Notes) | 185 | | | 185 | | 5.375% notes due 2043 (5.375% 2043 Notes) | 185 | | | 185 | |
4.40% notes due 2045 (4.40% 2045 Notes) | 4.40% notes due 2045 (4.40% 2045 Notes) | 2,250 | | | 2,250 | | 4.40% notes due 2045 (4.40% 2045 Notes) | 2,250 | | | 2,250 | |
4.563% notes due 2048 (4.563% 2048 Notes) | 4.563% notes due 2048 (4.563% 2048 Notes) | 1,415 | | | 1,415 | | 4.563% notes due 2048 (4.563% 2048 Notes) | 1,415 | | | 1,415 | |
3.375% notes due 2050 (3.375% 2050 Notes) | 3.375% notes due 2050 (3.375% 2050 Notes) | 2,250 | | | 2,250 | | 3.375% notes due 2050 (3.375% 2050 Notes) | 2,250 | | | 2,250 | |
4.663% notes due 2051 (4.663% 2051 Notes) | 4.663% notes due 2051 (4.663% 2051 Notes) | 3,541 | | | 3,541 | | 4.663% notes due 2051 (4.663% 2051 Notes) | 3,541 | | | 3,541 | |
3.00% notes due 2052 (3.00% 2052 Notes) | 3.00% notes due 2052 (3.00% 2052 Notes) | 1,350 | | | — | | 3.00% notes due 2052 (3.00% 2052 Notes) | 1,350 | | | 1,350 | |
4.20% notes due 2052 (4.20% 2052 Notes) | | 4.20% notes due 2052 (4.20% 2052 Notes) | 1,000 | | | — | |
2.77% notes due 2053 (2.77% 2053 Notes) | 2.77% notes due 2053 (2.77% 2053 Notes) | 940 | | | 940 | | 2.77% notes due 2053 (2.77% 2053 Notes) | 940 | | | 940 | |
4.40% notes due 2062 (4.40% 2062 Notes) | | 4.40% notes due 2062 (4.40% 2062 Notes) | 1,250 | | | — | |
Other notes due 2097 | Other notes due 2097 | 100 | | | 100 | | Other notes due 2097 | 100 | | | 100 | |
Unamortized bond discounts, premiums and issuance costs, net | Unamortized bond discounts, premiums and issuance costs, net | (1,221) | | | (1,188) | | Unamortized bond discounts, premiums and issuance costs, net | (1,253) | | | (1,213) | |
Fair value adjustments | Fair value adjustments | 371 | | | 566 | | Fair value adjustments | (53) | | | 284 | |
Other | Other | 15 | | | 5 | | Other | 14 | | | 15 | |
Total carrying value of debt | Total carrying value of debt | 37,579 | | | 32,986 | | Total carrying value of debt | 36,854 | | | 33,309 | |
Less current portion | Less current portion | (4,288) | | | (91) | | Less current portion | (844) | | | (87) | |
Total long-term debt | Total long-term debt | $ | 33,291 | | | $ | 32,895 | | Total long-term debt | $ | 36,010 | | | $ | 33,222 | |
There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.
During the three months ended September 30, 2021,March 31, 2022, we issued $5.0$4.0 billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $1.0 billion of the 4.20% 2052 Notes and $1.25 billion of the 1.65% 20284.40% 2062 Notes. The 3.00% 2029 Notes $1.25 billion ofwere issued to finance eligible projects that meet specified criteria to benefit the 2.00% 2032 Notes, $1.15 billion of the 2.80% 2041 Notes and $1.35 billion of the 3.00% 2052 Notes.environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity.
During the three months ended June 30, 2021, we entered into the following interest rate swap contracts: (i) $1.0 billion notional amount with respect to the 2.45% 2030 Notes, resulting in an effective interest rate of three-month LIBOR plus 1.0% for that portion of the notes, and (ii) $500 million notional amount with respect to the 2.30% 2031 Notes, resulting in an effective interest rate of three-month LIBOR plus 0.8% for that portion of the notes.
11.10. Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | |
| 2021 | | 2020 |
| Shares | | Dollars | | Shares | | Dollars |
First quarter | 3.7 | | | $ | 865 | | | 4.3 | | | $ | 933 | |
Second quarter | 6.5 | | | 1,592 | | | 2.6 | | | 591 | |
Third quarter | 4.6 | | | 1,069 | | | 3.0 | | | 752 | |
Total stock repurchases | 14.8 | | | $ | 3,526 | | | 9.9 | | | $ | 2,276 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 |
| Shares | | Dollars | | Shares | | Dollars |
First quarter | 24.6 | | | $ | 5,410 | | | 3.7 | | | $ | 865 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
On February 24, 2022, the Company entered into ASR agreements with 3 third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion on February 25, 2022, to the Dealers and received and retired an initial 23.3 million shares of the Company’s common stock from the Dealers. The payments were recorded as reductions to shareholders’ equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company’s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In March 2021, our Boardtotal, we repurchased 24.6 million shares of Directors increasedcommon stock in the amount authorizedfirst quarter of 2022, including shares received under our stock repurchase program by an additional $3.4 billion. the ASR agreements.
As of September 30, 2021, $2.9March 31, 2022, $4.6 billion of authorizationauthorization remained available under our stock repurchase program.
In October 2021, the Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.5 billion.
Dividends
In July 2021, March 2021 and December 2020,2022, the Board of Directors declared a quarterly cash dividend of $1.76$1.94 per share, which werewill be paid in September 2021, June 2021 and March 2021, respectively.2022. In OctoberDecember 2021, the Board of Directors declared a quarterly cash dividend of $1.76$1.94 per share, which will bewas paid on December 8, 2021.in March 2022.
Accumulated other comprehensive income (loss)
The components of Accumulated other comprehensive income (loss) (AOCI)AOCI were as follows (in millions):
| | | Foreign currency translation | | Cash flow hedges | | Available-for-sale securities | | Other | | AOCI | | Foreign currency translation | | Cash flow hedges | | Available-for-sale securities | | Other | | AOCI |
Balance as of December 31, 2020 | $ | (709) | | | $ | (263) | | | $ | 1 | | | $ | (14) | | | $ | (985) | | |
Balance as of December 31, 2021 | | Balance as of December 31, 2021 | $ | (844) | | | $ | 61 | | | $ | — | | | $ | (13) | | | $ | (796) | |
| Foreign currency translation adjustments | Foreign currency translation adjustments | (39) | | | — | | | — | | | — | | | (39) | | Foreign currency translation adjustments | (51) | | | — | | | — | | | — | | | (51) | |
Unrealized gains | Unrealized gains | — | | | 108 | | | — | | | — | | | 108 | | Unrealized gains | — | | | 56 | | | — | | | — | | | 56 | |
Reclassification adjustments to income | Reclassification adjustments to income | — | | | 133 | | | — | | | — | | | 133 | | Reclassification adjustments to income | — | | | 51 | | | — | | | — | | | 51 | |
Other | — | | | — | | | — | | | 1 | | | 1 | | |
| Income taxes | Income taxes | — | | | (51) | | | — | | | — | | | (51) | | Income taxes | — | | | (23) | | | — | | | — | | | (23) | |
Balance as of March 31, 2021 | (748) | | | (73) | | | 1 | | | (13) | | | (833) | | |
Balance as of March 31, 2022 | | Balance as of March 31, 2022 | $ | (895) | | | $ | 145 | | | $ | — | | | $ | (13) | | | $ | (763) | |
| Foreign currency translation adjustments | 14 | | | — | | | — | | | — | | | 14 | | |
Unrealized losses | — | | | (31) | | | — | | | — | | | (31) | | |
Reclassification adjustments to income | — | | | (28) | | | — | | | — | | | (28) | | |
Other | — | | | — | | | — | | | (1) | | | (1) | | |
Income taxes | — | | | 11 | | | — | | | — | | | 11 | | |
Balance as of June 30, 2021 | (734) | | | (121) | | | 1 | | | (14) | | | (868) | | |
Foreign currency translation adjustments | (35) | | | — | | | — | | | — | | | (35) | | |
Unrealized gains (losses) | — | | | 16 | | | (1) | | | — | | | 15 | | |
Reclassification adjustments to income | — | | | 109 | | | — | | | — | | | 109 | | |
Other | — | | | — | | | — | | | (3) | | | (3) | | |
Income taxes | — | | | (26) | | | — | | | — | | | (26) | | |
Balance as of September 30, 2021 | $ | (769) | | | $ | (22) | | | $ | — | | | $ | (17) | | | $ | (808) | | |
|
Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | |
Components of AOCI | | 2021 | | 2020 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | | | | | | |
Foreign currency contract (losses) gains | | $ | (5) | | | $ | 41 | | | Product sales |
Cross-currency swap contract (losses) gains | | (104) | | | 183 | | | Other income, net |
| | | | | | |
| | (109) | | | 224 | | | Income before income taxes |
| | 23 | | | (49) | | | Provision for income taxes |
| | $ | (86) | | | $ | 175 | | | Net income |
Available-for-sale securities: | | | | | | |
Net realized gains | | $ | — | | | $ | — | | | Other income, net |
| | — | | | — | | | Provision for income taxes |
| | $ | — | | | $ | — | | | Net income |
| | | | | | |
| | Nine months ended September 30, | | |
Components of AOCI | | 2021 | | 2020 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | | | | | | |
Foreign currency contract (losses) gains | | $ | (24) | | | $ | 158 | | | Product sales |
Cross-currency swap contract (losses) gains | | (190) | | | 101 | | | Other income, net |
| | | | | | |
| | (214) | | | 259 | | | Income before income taxes |
| | 45 | | | (57) | | | Provision for income taxes |
| | $ | (169) | | | $ | 202 | | | Net income |
Available-for-sale securities: | | | | | | |
Net realized gains | | $ | — | | | $ | 33 | | | Other income, net |
| | — | | | (7) | | | Provision for income taxes |
| | $ | — | | | $ | 26 | | | Net income |
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended March 31, | | |
Components of AOCI | | 2022 | | 2021 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | | | | | | |
Foreign currency contract gains (losses) | | $ | 27 | | | $ | (1) | | | Product sales |
Cross-currency swap contract losses | | (78) | | | (132) | | | Other (expense) income, net |
| | | | | | |
| | (51) | | | (133) | | | Income before income taxes |
| | 11 | | | 28 | | | Provision for income taxes |
| | $ | (40) | | | $ | (105) | | | Net income |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
12.
11. Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
| | | | | | | | |
Level 1 | — | Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access |
Level 2 | — | Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs |
Level 3 | — | Valuations based on inputs that are unobservable and significant to the overall fair value measurement |
The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
| | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | |
| Fair value measurement as of September 30, 2021, using: | | Total | |
Fair value measurement as of March 31, 2022, using: | | Fair value measurement as of March 31, 2022, using: | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | Total |
Assets: | Assets: | | | | | | | | | Assets: | | |
Available-for-sale securities: | Available-for-sale securities: | | Available-for-sale securities: | |
U.S. Treasury notes | U.S. Treasury notes | | $ | 51 | | | $ | — | | | $ | — | | | $ | 51 | | U.S. Treasury notes | | $ | 16 | | | $ | — | | | $ | — | | | $ | 16 | |
U.S. Treasury bills | U.S. Treasury bills | | 3,900 | | | — | | | — | | | 3,900 | | U.S. Treasury bills | | — | | | — | | | — | | | — | |
| Money market mutual funds | Money market mutual funds | | 8,323 | | | — | | | — | | | 8,323 | | Money market mutual funds | | 5,837 | | | — | | | — | | | 5,837 | |
Other short-term interest-bearing securities | Other short-term interest-bearing securities | | — | | | 1 | | | — | | | 1 | | Other short-term interest-bearing securities | | — | | | — | | | — | | | — | |
Equity securities | Equity securities | | 608 | | | — | | | 257 | | | 865 | | Equity securities | | 473 | | | — | | | 170 | | | 643 | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | — | | | 127 | | | — | | | 127 | | Foreign currency contracts | | — | | | 235 | | | — | | | 235 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 119 | | | — | | | 119 | | Cross-currency swap contracts | | — | | | 65 | | | — | | | 65 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | 29 | | | — | | | 29 | | Interest rate swap contracts | | — | | | — | | | — | | | — | |
| Total assets | Total assets | | $ | 12,882 | | | $ | 276 | | | $ | 257 | | | $ | 13,415 | | Total assets | | $ | 6,326 | | | $ | 300 | | | $ | 170 | | | $ | 6,796 | |
| Liabilities: | Liabilities: | | Liabilities: | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | $ | — | | | $ | 54 | | | $ | — | | | $ | 54 | | Foreign currency contracts | | $ | — | | | $ | 51 | | | $ | — | | | $ | 51 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 360 | | | — | | | 360 | | Cross-currency swap contracts | | — | | | 358 | | | — | | | 358 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | 105 | | | — | | | 105 | | Interest rate swap contracts | | — | | | 456 | | | — | | | 456 | |
Contingent consideration obligations | Contingent consideration obligations | | — | | | — | | | 35 | | | 35 | | Contingent consideration obligations | | — | | | — | | | 330 | | | 330 | |
Total liabilities | Total liabilities | | $ | — | | | $ | 519 | | | $ | 35 | | | $ | 554 | | Total liabilities | | $ | — | | | $ | 865 | | | $ | 330 | | | $ | 1,195 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | |
| | | | | |
Fair value measurement as of December 31, 2020, using: | | | | | Total |
Assets: | | | | | | | | |
Available-for-sale securities: | | | | | | | | |
U.S. Treasury notes | | $ | 130 | | | $ | — | | | $ | — | | | $ | 130 | |
U.S. Treasury bills | | 4,948 | | | — | | | — | | | 4,948 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Money market mutual funds | | 4,765 | | | — | | | — | | | 4,765 | |
Other short-term interest-bearing securities | | — | | | 2 | | | — | | | 2 | |
Equity securities | | 477 | | | — | | | — | | | 477 | |
Derivatives: | | | | | | | | |
Foreign currency contracts | | — | | | 28 | | | — | | | 28 | |
Cross-currency swap contracts | | — | | | 255 | | | — | | | 255 | |
Interest rate swap contracts | | — | | | 66 | | | — | | | 66 | |
Total assets | | $ | 10,320 | | | $ | 351 | | | $ | — | | | $ | 10,671 | |
| | | | | | | | |
Liabilities: | | | | | | | | |
Derivatives: | | | | | | | | |
Foreign currency contracts | | $ | — | | | $ | 237 | | | $ | — | | | $ | 237 | |
Cross-currency swap contracts | | — | | | 318 | | | — | | | 318 | |
Interest rate swap contracts | | — | | | 15 | | | — | | | 15 | |
Contingent consideration obligations | | — | | | — | | | 33 | | | 33 | |
Total liabilities | | $ | — | | | $ | 570 | | | $ | 33 | | | $ | 603 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | |
| | | | | |
Fair value measurement as of December 31, 2021, using: | | | | | Total |
Assets: | | | | | | | | |
Available-for-sale securities: | | | | | | | | |
U.S. Treasury notes | | $ | 47 | | | $ | — | | | $ | — | | | $ | 47 | |
U.S. Treasury bills | | 1,400 | | | — | | | — | | | 1,400 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Money market mutual funds | | 5,856 | | | — | | | — | | | 5,856 | |
Other short-term interest-bearing securities | | — | | | 1 | | | — | | | 1 | |
Equity securities | | 611 | | | — | | | 220 | | | 831 | |
Derivatives: | | | | | | | | |
Foreign currency contracts | | — | | | 183 | | | — | | | 183 | |
Cross-currency swap contracts | | — | | | 66 | | | — | | | 66 | |
Interest rate swap contracts | | — | | | 16 | | | — | | | 16 | |
Total assets | | $ | 7,914 | | | $ | 266 | | | $ | 220 | | | $ | 8,400 | |
| | | | | | | | |
Liabilities: | | | | | | | | |
Derivatives: | | | | | | | | |
Foreign currency contracts | | $ | — | | | $ | 39 | | | $ | — | | | $ | 39 | |
Cross-currency swap contracts | | — | | | 339 | | | — | | | 339 | |
Interest rate swap contracts | | — | | | 156 | | | — | | | 156 | |
Contingent consideration obligations | | — | | | — | | | 342 | | | 342 | |
Total liabilities | | $ | — | | | $ | 534 | | | $ | 342 | | | $ | 876 | |
Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based upon a combination of entity-specific financial informationmarket performance and publicly available market information for similar companies that have actively traded equity securities.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P),S&P, Moody’s Investors Service, Inc. (Moody’s) or Fitch Ratings, Inc. (Fitch).Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 13,12, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 13,12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 13,12, Derivative instruments.
Contingent consideration obligations
As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the threerelated contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and nine months ended September 30, 2021product candidates acquired in business combinations, and 2020, there were no material remeasurementsthey are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of assetsthe obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.
Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):
| | | | | | | | | | | | | | |
| | Three Months Ended March 31, |
| | 2022 | | 2021 |
Beginning balance | | $ | 342 | | | $ | 33 | |
| | | | |
Payments | | (2) | | | (1) | |
Net changes in valuations | | (10) | | | 7 | |
Ending balance | | $ | 330 | | | $ | 39 | |
As of March 31, 2022 and liabilities thatDecember 31, 2021, our contingent consideration obligations are not measured at fair value on a recurring basis.primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6 billion upon achieving separate development and regulatory milestones with regard to various R&D programs. See Note 2, Acquisitions.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of September 30, 2021March 31, 2022 and December 31, 2020,2021, the aggregate fair values of our borrowings were $42.2$38.4 billion and $39.4$37.9 billion, respectively, and the carrying values were $37.6$36.9 billion and $33.0$33.3 billion, respectively.
During the three months ended March 31, 2022 and 2021, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.
Investment in BeiGene
We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of March 31, 2022 and December 31, 2021, the fair values were $3.6 billion and $5.1 billion, and the carrying values were $2.6 billion and $2.8 billion, respectively.
During the three months ended March 31, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.
13.
12. Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.
As of September 30, 2021March 31, 2022 and December 31, 2020,2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.7$5.6 billion and $5.1$5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.
The notional amounts and interest rates of our cross-currency swaps as of September 30, 2021,March 31, 2022, were as follows (notional amounts in millions):
| | | Foreign currency | | U.S. dollars | | Foreign currency | | U.S. dollars |
Hedged notes | Hedged notes | | Notional amounts | | Interest rates | | Notional amounts | | Interest rates | Hedged notes | | Notional amounts | | Interest rates | | Notional amounts | | Interest rates |
| 1.25% 2022 euro Notes | | € | 1,250 | | | 1.3 | % | | $ | 1,388 | | | 3.2 | % | |
0.41% 2023 Swiss franc Bonds | 0.41% 2023 Swiss franc Bonds | | CHF | 700 | | | 0.4 | % | | $ | 704 | | | 3.4 | % | 0.41% 2023 Swiss franc Bonds | | CHF | 700 | | | 0.4 | % | | $ | 704 | | | 3.4 | % |
2.00% 2026 euro Notes | 2.00% 2026 euro Notes | | € | 750 | | | 2.0 | % | | $ | 833 | | | 3.9 | % | 2.00% 2026 euro Notes | | € | 750 | | | 2.0 | % | | $ | 833 | | | 3.9 | % |
5.50% 2026 pound sterling Notes | 5.50% 2026 pound sterling Notes | | £ | 475 | | | 5.5 | % | | $ | 747 | | | 6.0 | % | 5.50% 2026 pound sterling Notes | | £ | 475 | | | 5.5 | % | | $ | 747 | | | 6.0 | % |
4.00% 2029 pound sterling Notes | 4.00% 2029 pound sterling Notes | | £ | 700 | | | 4.0 | % | | $ | 1,111 | | | 4.5 | % | 4.00% 2029 pound sterling Notes | | £ | 700 | | | 4.0 | % | | $ | 1,111 | | | 4.5 | % |
In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the ninethree months ended September 30, 2021,March 31, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
| | | | Three months ended September 30, | | Nine months ended September 30, | | | Three months ended March 31, | |
Derivatives in cash flow hedging relationships | Derivatives in cash flow hedging relationships | | 2021 | | 2020 | | 2021 | | 2020 | Derivatives in cash flow hedging relationships | | 2022 | | 2021 | |
Foreign currency contracts | Foreign currency contracts | | $ | 136 | | | $ | (163) | | | $ | 273 | | | $ | (25) | | Foreign currency contracts | | $ | 78 | | | $ | 183 | | |
Cross-currency swap contracts | Cross-currency swap contracts | | (120) | | | 223 | | | (180) | | | (107) | | Cross-currency swap contracts | | (22) | | | (75) | | |
| Total unrealized gains (losses) | | $ | 16 | | | $ | 60 | | | $ | 93 | | | $ | (132) | | |
Total unrealized gains | | Total unrealized gains | | $ | 56 | | | $ | 108 | | |
Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of September 30, 2021both March 31, 2022 and December 31, 2020,2021, we had interest rate swap contracts with aggregate notional amounts of $7.4$6.7 billion and $5.9 billion, respectively, that hedge certain portions of our long-term debt issuances. During the three months ended June 30, 2021, we entered into $1.5 billion of interest rate swap contracts to hedge portions of our 2.45% 2030 Notes and 2.30% 2031 Notes (see Note 10, Financing arrangements).
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
| | | Carrying amounts of hedged liabilities(1) | | Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) | | Carrying amounts of hedged liabilities(1) | | Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) |
Condensed Consolidated Balance Sheets locations | Condensed Consolidated Balance Sheets locations | | September 30, 2021 | | December 31, 2020 | | September 30, 2021 | | December 31, 2020 | Condensed Consolidated Balance Sheets locations | | March 31, 2022 | | December 31, 2021 | | March 31, 2022 | | December 31, 2021 |
Current portion of long-term debt | Current portion of long-term debt | | $ | 840 | | | $ | 89 | | | $ | 90 | | | $ | 89 | | Current portion of long-term debt | | $ | 83 | | | $ | 85 | | | $ | 83 | | | $ | 85 | |
Long-term debt | Long-term debt | | $ | 6,809 | | | $ | 6,258 | | | $ | 281 | | | $ | 477 | | Long-term debt | | $ | 6,395 | | | $ | 6,729 | | | $ | (136) | | | $ | 199 | |
____________
(1) Current portion of long-term debt includes $87$83 million and $89$85 million of carrying value with discontinued hedging relationships as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively. Long-term debt includes $460$419 million and $525$440 million of carrying value with discontinued hedging relationships as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively.
(2) Current portion of long-term debt includes $87$83 million and $89$85 million of hedging adjustments on discontinued hedging relationships as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively. Long-term debt includes $360$319 million and $425$340 million of hedging adjustments on discontinued hedging relationships as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively.
Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
| | | | Three months ended September 30, 2021 | | Nine months ended September 30, 2021 | | Three months ended March 31, 2022 | |
| | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other (expense) income, net | | Interest expense, net | |
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 6,320 | | | $ | 73 | | | $ | (296) | | | $ | 18,026 | | | $ | 97 | | | $ | (862) | | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 5,731 | | | $ | (530) | | | $ | (295) | | |
The effects of cash flow and fair value hedging: | The effects of cash flow and fair value hedging: | | The effects of cash flow and fair value hedging: | | |
Losses on cash flow hedging relationships reclassified out of AOCI: | | |
Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | | Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | | |
Foreign currency contracts | Foreign currency contracts | | $ | (5) | | | $ | — | | | $ | — | | | $ | (24) | | | $ | — | | | $ | — | | Foreign currency contracts | | $ | 27 | | | $ | — | | | $ | — | | |
Cross-currency swap contracts | Cross-currency swap contracts | | $ | — | | | $ | (104) | | | $ | — | | | $ | — | | | $ | (190) | | | $ | — | | Cross-currency swap contracts | | $ | — | | | $ | (78) | | | $ | — | | |
| Gains (losses) on fair value hedging relationships—interest rate swap agreements: | Gains (losses) on fair value hedging relationships—interest rate swap agreements: | | Gains (losses) on fair value hedging relationships—interest rate swap agreements: | | |
Hedged items(1) | Hedged items(1) | | $ | — | | | $ | — | | | $ | 54 | | | $ | — | | | $ | — | | | $ | 195 | | Hedged items(1) | | $ | — | | | $ | — | | | $ | 337 | | |
Derivatives designated as hedging instruments | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | (31) | | | $ | — | | | $ | — | | | $ | (128) | | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | (315) | | |
| | | | Three months ended September 30, 2020 | | Nine months ended September 30, 2020 | | Three months ended March 31, 2021 | |
| | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other (expense) income, net | | Interest expense, net | |
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 6,104 | | | $ | 55 | | | $ | (302) | | | $ | 17,906 | | | $ | 69 | | | $ | (944) | | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 5,592 | | | $ | 13 | | | $ | (285) | | |
The effects of cash flow and fair value hedging: | The effects of cash flow and fair value hedging: | | The effects of cash flow and fair value hedging: | | |
Gains on cash flow hedging relationships reclassified out of AOCI: | | |
Losses on cash flow hedging relationships reclassified out of AOCI: | | Losses on cash flow hedging relationships reclassified out of AOCI: | | |
Foreign currency contracts | Foreign currency contracts | | $ | 41 | | | $ | — | | | $ | — | | | $ | 158 | | | $ | — | | | $ | — | | Foreign currency contracts | | $ | (1) | | | $ | — | | | $ | — | | |
Cross-currency swap contracts | Cross-currency swap contracts | | $ | — | | | $ | 183 | | | $ | — | | | $ | — | | | $ | 101 | | | $ | — | | Cross-currency swap contracts | | $ | — | | | $ | (132) | | | $ | — | | |
| Gains (losses) on fair value hedging relationships—interest rate swap agreements: | Gains (losses) on fair value hedging relationships—interest rate swap agreements: | | Gains (losses) on fair value hedging relationships—interest rate swap agreements: | | |
Hedged items(1) | Hedged items(1) | | $ | — | | | $ | — | | | $ | 35 | | | $ | — | | | $ | — | | | $ | 215 | | Hedged items(1) | | $ | — | | | $ | — | | | $ | 175 | | |
Derivatives designated as hedging instruments | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | (13) | | | $ | — | | | $ | — | | | $ | (150) | | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | (152) | | |
__________
(1) Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2021, theMarch 31, 2022, we expected to reclassify $120 million of net gains expected to be reclassified on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months are not material.months.
Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of September 30, 2021March 31, 2022 and December 31, 2020,2021, the total notional amounts of these foreign currency forward contracts were $0.7 billion$655 million and $1.0 billion,$680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and nine months ended September 30, 2021March 31, 2022 and 2020.2021.
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
| | | | Derivative assets | | Derivative liabilities | | | Derivative assets | | Derivative liabilities |
September 30, 2021 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values | |
March 31, 2022 | | March 31, 2022 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values |
Derivatives designated as hedging instruments: | Derivatives designated as hedging instruments: | | | | | | | | | Derivatives designated as hedging instruments: | | | | | | | | |
Foreign currency contracts | Foreign currency contracts | | Other current assets/ Other noncurrent assets | | $ | 127 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 54 | | Foreign currency contracts | | Other current assets/ Other noncurrent assets | | $ | 235 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 51 | |
Cross-currency swap contracts | Cross-currency swap contracts | | Other current assets/ Other noncurrent assets | | 119 | | | Accrued liabilities/ Other noncurrent liabilities | | 360 | | Cross-currency swap contracts | | Other current assets/ Other noncurrent assets | | 65 | | | Accrued liabilities/ Other noncurrent liabilities | | 358 | |
Interest rate swap contracts | Interest rate swap contracts | | Other current assets/ Other noncurrent assets | | 29 | | | Accrued liabilities/ Other noncurrent liabilities | | 105 | | Interest rate swap contracts | | Other current assets/ Other noncurrent assets | | — | | | Accrued liabilities/ Other noncurrent liabilities | | 456 | |
| Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments | | $ | 275 | | | $ | 519 | | Total derivatives designated as hedging instruments | | $ | 300 | | | $ | 865 | |
|
| | | | Derivative assets | | Derivative liabilities | | | Derivative assets | | Derivative liabilities |
December 31, 2020 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values | |
December 31, 2021 | | December 31, 2021 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values |
Derivatives designated as hedging instruments: | Derivatives designated as hedging instruments: | | | | | | | | | Derivatives designated as hedging instruments: | | | | | | | | |
Foreign currency contracts | Foreign currency contracts | | Other current assets/ Other noncurrent assets | | $ | 28 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 237 | | Foreign currency contracts | | Other current assets/ Other noncurrent assets | | $ | 183 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 39 | |
Cross-currency swap contracts | Cross-currency swap contracts | | Other current assets/ Other noncurrent assets | | 255 | | | Accrued liabilities/ Other noncurrent liabilities | | 318 | | Cross-currency swap contracts | | Other current assets/ Other noncurrent assets | | 66 | | | Accrued liabilities/ Other noncurrent liabilities | | 339 | |
| Interest rate swap contracts | Interest rate swap contracts | | Other current assets/ Other noncurrent assets | | 66 | | | Accrued liabilities/ Other noncurrent liabilities | | 15 | | Interest rate swap contracts | | Other current assets/ Other noncurrent assets | | 16 | | | Accrued liabilities/ Other noncurrent liabilities | | 156 | |
Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments | | $ | 349 | | | $ | 570 | | Total derivatives designated as hedging instruments | | $ | 265 | | | $ | 534 | |
|
Our derivative contracts that were in liability positions as of September 30, 2021,March 31, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.
13. Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2020,2021, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; and in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; in Note 12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended June 30, 2021.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; and in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; in Note 12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2021; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended June 30, 2021, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; and in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; in Note 12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2021; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended June 30, 2021, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
Abbreviated New Drug Application (ANDA)Repatha Patent Litigation
Otezla® ANDA Patent Litigation
Amgen Inc., et al. v. Sandoz Inc.,Sanofi, et al.
On SeptemberMarch 28, 2022, Amgen filed a reply brief in support of its petition for certiorari to the U.S. Supreme Court. On April 18, 2022, the Supreme Court requested that the Office of the Solicitor General of the United States submit a brief providing the government’s view on the issues raised by Amgen’s petition.
Patent Disputes in the International Region
On March 23, 2022, Amgen filed counterclaims alleging that PRALUENT® infringes Amgen’s European Patent 2,641,917 (the ‘917 Patent). A European Patent Office (EPO) opposition to the ‘917 Patent, filed by Sanofi on February 5, 2021, consistent with its September 20, 2021 opinionis pending, and order,the hearing before the EPO’s Opposition Division is scheduled for February 21, 2023.
NEUPOGEN (filgrastim)/Neulasta Patent Litigation
Amgen Inc., et al. v. Hospira Inc. et al.
On March 18, 2022, the parties filed a stipulation of dismissal, and the U.S. District Court for the District of New JerseyDelaware (the New JerseyDelaware District Court) entered final judgment in favordismissed the case on March 21, 2022.
Patent Trial and Appeal Board (PTAB) Challenge
Apotex PTAB Challenge
On April 4, 2022, Amgen’s appeal of Amgen and against Zydus Pharmaceuticals (USA) Inc. (Zydus) with respect tothe PTAB’s decision, holding all claims 3 and 6 of Amgen’s U.S. Patent No. 7,427,6388,952,138 (the ’638‘138 Patent), claim 6 of U.S. Patent No. 8,455,536 (the ’536 Patent) and claims 2 and 27 of U.S. Patent No. 8,093,283 (the ‘283 Patent); and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of U.S. Patent No. 7,893,101 (the ‘101 Patent) and claims 2, 19 and 21 of U.S. Patent No. 10,092,541 (the ’541 Patent). The final judgment ordered that the effective date of any final approval by the U.S. Food and Drug Administration (FDA) of Zydus’s ANDA must be after expiration of the 3 infringed patents (the ’638, ’536 and ’283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus’s generic apremilast products during the term of the three infringed patents.
On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz Inc. (Sandoz) with respect to claims 3 and 6 of the ’638 Patent, claim 6 of the ’536 Patent and claims 1 and 15 of the ’101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the ’541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz’s ANDA must be after expiration of the 3 infringed patents (the ’638, ’536 and ’101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz’s generic apremilast products during the term of the 3 infringed patents.
Zydus and Amgen filed notices of appeal unpatentable, was submitted to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court) for determination on October 27, 2021 and October 28, 2021, respectively.
Sensipar® (cinacalcet) ANDA Patent Litigation
Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.)
the briefs without oral argument. On October 20, 2021, the U.S. District Court for the District of Delaware (the Delaware District Court) issued final judgment in favor of Piramal Healthcare UK Limited and Slate Run Pharmaceuticals LLC.
ENBREL Patent Litigation
Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.
On November 2, 2021, Amgen and Samsung Bioepis Co., Ltd. (Bioepis), with the consent of Hoffmann-La Roche Inc. (Roche), jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche’s U.S. Patent No. 8,163,522.
Repatha® Patent Litigation
Patent Disputes in the International Region
National litigations in the United Kingdom, France, the Netherlands and Italy have been settled. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron Pharmaceuticals, Inc. have filed actions claiming they are entitled to damages arising from the provisional enforcement of an injunction against PRALUENT® that was lifted after the European Patent Office Technical Board of Appeal’s October 29, 2020 ruling that certain claims encompassing PRALUENT® in Amgen’s European Patent No. 2,215,124 were invalid.
NEUPOGEN® (filgrastim)/Neulasta® Patent Litigation
Amgen Inc., et al. v. Pfizer Inc. et al.
On September 8, 2021, pursuant to joint stipulation, the Delaware District Court dismissed the lawsuits regarding U.S. Patent Nos. 9,643,997 and 10,577,392.
Patent Trial and Appeal Board (PTAB) Challenge
Apotex PTAB Challenge
On September 2, 2021,14, 2022, the Federal Circuit Court issued a remandheld that the PTAB misconstrued the patent claims and reversed the PTAB’s decision because Apotex failed to permit Amgen to request rehearingprove the invention of the PTAB’s final written decision holding that all claims of U.S.‘138 Patent No. 8.952,138 as unpatentable.
Pfizer
Pfizer PTAB Challenge
On February 10, 2021, Hospira, Inc. and Pfizer Inc. (collectively, Pfizer)On March 18, 2022, the parties filed a petitionjoint motion to instituteterminate the inter partes review (IPR) proceeding at the U.S. Patent and Trademark Office (USPTO) of U.S. Patent No. 8,273,707 (the ’707 Patent), challenging8,273,707. On April 20, 2022, the PTAB granted the motion and terminated the proceeding.
Antitrust Class Action
Sensipar Antitrust Class Actions
On March 11, 2022, the Delaware District Court granted defendants’ (including Amgen’s) motion to dismiss except as to the reverse payment claim and various state law claims from 10 of the ’707 Patent as unpatentable. Amgen’s preliminary response was filed on May 18, 2021.
On August 17, 2021, the PTAB of the USPTO granted Pfizer’s petition to institute IPR of the ’707 Patent. On August 23, 2021, the PTAB issued the schedule for the proceeding, including oral argument (if requested) on May 18, 2022.
Breach of Contract Action
Novartis Pharma AG v. Amgen Inc.
On October 26, 2021, the U.S. District Court for the Southern District of New York held a status conference with the parties and set the dates for Novartis Pharma AG’s (Novartis) opening brief for its motion for partial summary judgment on 2 claims, fraudulent inducement and negligent misrepresentation, to be due on January 14, 2022, Amgen’s opposition to be due on February 14, 2022 and Novartis’ reply to be due on March 10, 2022. This motion, if granted, will not dispose of the entire case as other claims related to breach of contract remain pending.states in which plaintiffs reside.
U.S. Tax Litigation
Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue
See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company’s petition in the U.S. Tax Court.
15. Subsequent event
On October 19, 2021, Amgen completed its acquisition of Teneobio, Inc. (Teneobio), a privately held, clinical-stage biotechnology company developing a new class of biologics called heavy-chain only antibodies (HCAbs). Amgen acquired all outstanding shares in exchange for a $900 million upfront payment, as well as future contingent milestone payments potentially worth up to an additional $1.6 billion in cash upon the achievement of certain development and regulatory events.
The accounting impact of this acquisition and the results of operations for Teneobio will be included in our consolidated financial statements beginning in the fourth quarter of 2021. The initial accounting for this acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.
| | | | | |
Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A)MD&A is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2020, and our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.
Forward-looking statements
This report and other documents we file with the Securities and Exchange Commission (SEC)SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume” and “continue” as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.
Overview
Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Our principal products—those with the most significant annual commercial sales—products are ENBREL, Prolia,®, XGEVA, Otezla,®, XGEVA®, Aranesp, Neulasta,®, Aranesp®, Repatha,® KYPROLIS and KYPROLIS®.Nplate. We also marketmarket a number of other products, including MVASI,® (bevacizumab-awwb), Nplate® (romiplostim), Vectibix,® (panitumumab), EVENITY, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, KANJINTI,® (trastuzumab-anns), EPOGEN® (epoetin alfa), EVENITY® (romosozumab-aqqg), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv,® (etelcalcetide), LUMAKRAS/LUMYKRAS, NEUPOGEN,®, Sensipar®/ Sensipar/Mimpara™ (cinacalcet) and LUMAKRAS®/LUMYKRAS™ (sotorasib).TEZSPIRE.
COVID-19 pandemic
A novel strain of coronavirus (SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, causing coronavirus disease 19, or COVID-19) was declared a global pandemic by the World Health Organization on March 11, 2020. Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic’s effects on our global operations. We continue to take appropriate steps to minimize risks to our employees, a significant number of whom have continued to work virtually. Employee access to company facilities has been in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines.
Since the beginning of the COVID-19 pandemic, we have seen changes in demand for some of our products driven by changes in the frequency of patient visits to doctors’ offices that has impacted providingthe provision of treatments to existing patients and reduced diagnoses in new patients. Through the third quarter,During 2021, there has beenwas gradual recovery in both patient visits and diagnoses although overall these remain belowthat approached pre-COVID-19 levels. Thelevels early in the fourth quarter. However, in late 2021, Omicron and other variants began to impact the healthcare sector and, as a result, COVID-19 continued to affect our business around the world through the first quarter of 2022. Going forward, we may experience ongoing variability in demand patterns from COVID-19 for 2022. Further, the cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continuecontinues to impact our business during the remainder of the year.business. We arewill continue to closely monitoringmonitor the effects of emerging COVID-19 variants on patient behavior and access.access to care.
Since early 2021, global vaccination efforts have been underwayunder way to control the pandemic. However, uncertainty remains as to the length of time required for vaccination of a meaningful portion of the population and as to the efficacy of such vaccinations on the trajectory of the pandemic. Challenges to vaccination efforts, new variants and other causes of virus spread may require governments to issue additional restrictions and/or order shutdowns in various geographies. As a result, we expect to see continued volatility for at least the duration of the pandemic as governments respond to current local conditions.
With respect to our drug development activities, we are continuously monitoring COVID-19 infection rates, including changes from new variants, and working to mitigate effects on future study enrollment in our clinical trials and evaluating the impactimpacts in all countries where our clinical trials occur. We remain focused on supporting our active clinical sites in their providingprovision of care forto patients and in our providingprovision of investigational drug supply.
Despite the ongoing pandemic and business impacts noted above, we believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in the capital-return and other business initiatives that we plan to pursue. For a discussion of the risks the COVID-19 pandemic presents to our results, see Risk Factors in Item 1A. Risk Factors in Part II herein and in Part I,1, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021.
Significant developments
Following is a summary of selected significant developments affecting our business that occurred since the filing of our QuarterlyAnnual Report on Form 10-Q10-K for the periodyear ended June 30,December 31, 2021. For additional developments or for a more comprehensive discussion of certain developments discussed below, see our Annual Report on Form 10-K for the year ended December 31, 2020, and our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021.
Business DevelopmentOperations
Acquisition
TeneobioNew manufacturing facilities
•On October 19, 2021, Amgen completed its acquisitionIn March 2022, we broke ground to build a drug substance plant in North Carolina that will increase our manufacturing network capacity.
Products/Pipeline
Oncology/Hematology
LUMAKRAS/LUMYKRAS
•In April 2022, we announced long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced NSCLC who received LUMAKRAS. Data from 174 heavily pre-treated patients (172 with baseline measurable lesion(s)) were featured in an oral presentation at the American Association for Cancer Research annual meeting. LUMAKRAS demonstrated a centrally confirmed ORR of Teneobio,40.7%, disease control rate of 83.7% and median duration of response of 12.3 months. The results also showed median PFS of 6.3 months and overall survival of 12.5 months, with 32.5% of patients still alive at two years. No new safety signals for LUMAKRAS were identified with the long-term follow-up.
Inflammation
ABP 654
•In April 2022, we announced preliminary results from a privately held, clinical-stage biotechnology company,Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA®.
Repatha
•In April 2022, we announced top-line results from the Repatha FOURIER-OLE studies, two open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial, composed of a study with 5,035 patients enrolled in Eastern Europe and the United States and a study with 1,600 patients enrolled in Western Europe. FOURIER-OLE was designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease. The FOURIER-OLE studies showed that Repatha, administered at 140 mg every two weeks or 420 mg monthly, was safe and well-tolerated. Patients received Repatha for $900 million as well as future contingent milestone payments potentially worthapproximately 5 years, with some patients receiving Repatha for up to 8.5 years in aggregate across the FOURIER and OLE studies. No new long-term safety findings were observed. In addition, medically significant and sustained reduction in low-density lipoprotein cholesterol (LDL-C) levels were observed in most patients, with greater than 85 percent of patients achieving an additional $1.6 billion uponLDL-C level of <40 mg/dL during the achievement of certain development and regulatory events.
OLE period.
Selected financial information
The following is an overview of our results of operations (in millions, except percentages and per-share data):
| | | Three months ended September 30, | | Nine months ended September 30, | | | Three months ended March 31, | | |
| | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change | | 2022 | | 2021 | | Change | |
Product sales | Product sales | | | | | | | | | | | | Product sales | | | | | | |
U.S. | U.S. | $ | 4,558 | | | $ | 4,618 | | | (1) | % | | $ | 12,835 | | | $ | 13,325 | | | (4) | % | U.S. | $ | 4,037 | | | $ | 3,903 | | | 3 | % | |
ROW | ROW | 1,762 | | | 1,486 | | | 19 | % | | 5,191 | | | 4,581 | | | 13 | % | ROW | 1,694 | | | 1,689 | | | — | % | |
Total product sales | Total product sales | 6,320 | | | 6,104 | | | 4 | % | | 18,026 | | | 17,906 | | | 1 | % | Total product sales | 5,731 | | | 5,592 | | | 2 | % | |
Other revenues | Other revenues | 386 | | | 319 | | | 21 | % | | 1,107 | | | 884 | | | 25 | % | Other revenues | 507 | | | 309 | | | 64 | % | |
Total revenues | Total revenues | $ | 6,706 | | | $ | 6,423 | | | 4 | % | | $ | 19,133 | | | $ | 18,790 | | | 2 | % | Total revenues | $ | 6,238 | | | $ | 5,901 | | | 6 | % | |
Operating expenses | Operating expenses | $ | 4,328 | | | $ | 3,970 | | | 9 | % | | $ | 13,798 | | | $ | 11,659 | | | 18 | % | Operating expenses | $ | 3,738 | | | $ | 3,772 | | | (1) | % | |
Operating income | Operating income | $ | 2,378 | | | $ | 2,453 | | | (3) | % | | $ | 5,335 | | | $ | 7,131 | | | (25) | % | Operating income | $ | 2,500 | | | $ | 2,129 | | | 17 | % | |
Net income | Net income | $ | 1,884 | | | $ | 2,021 | | | (7) | % | | $ | 3,994 | | | $ | 5,649 | | | (29) | % | Net income | $ | 1,476 | | | $ | 1,646 | | | (10) | % | |
Diluted EPS | Diluted EPS | $ | 3.31 | | | $ | 3.43 | | | (3) | % | | $ | 6.93 | | | $ | 9.54 | | | (27) | % | Diluted EPS | $ | 2.68 | | | $ | 2.83 | | | (5) | % | |
Diluted shares | Diluted shares | 570 | | | 589 | | | (3) | % | | 576 | | | 592 | | | (3) | % | Diluted shares | 551 | | | 581 | | | (5) | % | |
In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).
Total product sales increased for the three months ended September 30, 2021,March 31, 2022, primarily driven by higher unit demand for certain brands, including Repatha, Prolia,®, Repatha® EVENITY and EVENITY®,LUMAKRAS/LUMYKRAS, and by favorable changes to estimated sales deductions, partially offset by declines in the net selling prices of certain products. Total product sales increased forproducts and the nine months ended September 30, 2021, primarily driven by higher unit demand for certain brands, including Prolia®, Repatha® and MVASI®, partially offset by declines innegative impact of foreign currency exchange. For the net selling pricesremainder of certain products. We expect the trend of net selling price declines to continue to affect our business. Going forward,2022, we expect that net selling price declinesprices will becontinue to decline at a portfolio level driven by ENBREL, Neulasta®, Repatha® and some of our biosimilar products. There was gradual recovery throughincreased competition. In addition, in the thirdfirst quarter of 2021 in2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients resuming their treatments and in new patient starts, although overall, both numbers remain below pre-COVID-19 levels.work through deductibles.
Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician–patient interactions, which has led to delays in diagnoses and treatments, with varying degrees of impact across our portfolio. In general, declines in the sales of our products that were impacted by the dynamics of the pandemic were most significant in the early months of the pandemic, with product demand beginning to show some recovery in late 2020. ThroughDuring 2021, we observed gradual recovery from the third quarter ofCOVID-19 pandemic, with patient visits and diagnosis rates that approached pre-pandemic levels early in the fourth quarter. However, late in 2021, demand continuedOmicron and other variants began to gradually recover fromimpact the healthcare sector. This led to diminished capacity in the healthcare sector and reduced working days for our own sales force. In March and continuing into April we have seen the impact of Omicron in the pandemicU.S. recede, which allowed us to engage in increased field-facing activities. Provider and there was improvementpatient activity has also increased leading to improvements in patient visits and diagnoses. Healthcare provider activity also stabilized during the third quarter after having improved during the first half of 2021.demand for our products. However, the cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continuecontinues to impact our business for the remainder of the year.business. Given the unpredictable nature of the pandemic, we expect there could be ongoing intermittent disruptions in physician–patient interactions, and as a result, we continue to expectmay experience quarter-to-quarter variability. In addition, other changes in the healthcare ecosystem have the potential to introduce variability into product sales trends. For example, we expect changes in U.S. employment to leadhave led to changes to the insured population. Growth in numbers of Medicaid enrollees and uninsured individuals may have a negative impact on product demand and sales. Overall, uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic. See Risk Factors in Part II, Item 1A. of this Form 10-Q and Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021.
Other revenues increased for the three and nine months ended September 30, 2021,March 31, 2022, primarily driven by the sale of COVID-19 antibody material.
Operating expenses increaseddecreased for the three months ended September 30, 2021,March 31, 2022, primarily driven by an upfront paymentlower SG&A expense and expenses associated with cost-saving initiatives that occurred in the KKC licensing agreement. Operating expenses increased for the ninethree months ended September 30,March 31, 2021, primarily drivenpartially offset by IPR&D expense relatedhigher cost of sales. Our operating expenses are expected to be higher in the bemarituzumab program acquired as partremaining quarters of the Five Prime acquisitionyear as we continue to invest in innovation and by an upfront payment associated with the KKC licensing agreement.long-term growth.
Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activitiesactivities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material for the three and nine months ended September 30, 2021March 31, 2022 and 2020.2021.
Results of operations
Product sales
Worldwide product sales were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
ENBREL | $ | 1,289 | | | $ | 1,325 | | | (3) | % | | $ | 3,357 | | | $ | 3,724 | | | (10) | % |
Prolia® | 803 | | | 701 | | | 15 | % | | 2,375 | | | 2,014 | | | 18 | % |
Otezla® | 609 | | | 538 | | | 13 | % | | 1,619 | | | 1,578 | | | 3 | % |
XGEVA® | 517 | | | 481 | | | 7 | % | | 1,473 | | | 1,397 | | | 5 | % |
Neulasta® | 415 | | | 555 | | | (25) | % | | 1,383 | | | 1,757 | | | (21) | % |
Aranesp® | 396 | | | 384 | | | 3 | % | | 1,118 | | | 1,193 | | | (6) | % |
Repatha® | 272 | | | 205 | | | 33 | % | | 844 | | | 634 | | | 33 | % |
KYPROLIS® | 293 | | | 260 | | | 13 | % | | 824 | | | 793 | | | 4 | % |
Other products | 1,726 | | | 1,655 | | | 4 | % | | 5,033 | | | 4,816 | | | 5 | % |
Total product sales | $ | 6,320 | | | $ | 6,104 | | | 4 | % | | $ | 18,026 | | | $ | 17,906 | | | 1 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
ENBREL | $ | 862 | | | $ | 924 | | | (7) | % | | | | | | |
Prolia | 852 | | | 758 | | | 12 | % | | | | | | |
XGEVA | 502 | | | 468 | | | 7 | % | | | | | | |
Otezla | 451 | | | 476 | | | (5) | % | | | | | | |
Aranesp | 358 | | | 355 | | | 1 | % | | | | | | |
Neulasta | 348 | | | 482 | | | (28) | % | | | | | | |
Repatha | 329 | | | 286 | | | 15 | % | | | | | | |
KYPROLIS | 287 | | | 251 | | | 14 | % | | | | | | |
Nplate | 266 | | | 227 | | | 17 | % | | | | | | |
Other products | 1,476 | | | 1,365 | | | 8 | % | | | | | | |
Total product sales | $ | 5,731 | | | $ | 5,592 | | | 2 | % | | | | | | |
Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors; and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2020:2021: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021, in (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.Sales.
ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
| | | Three months ended September 30, | | Nine months ended September 30, | | | Three months ended March 31, | | |
| | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change | | 2022 | | 2021 | | Change | |
ENBREL — U.S. | ENBREL — U.S. | $ | 1,263 | | | $ | 1,289 | | | (2) | % | | $ | 3,270 | | | $ | 3,619 | | | (10) | % | ENBREL — U.S. | $ | 843 | | | $ | 894 | | | (6) | % | |
ENBREL — Canada | ENBREL — Canada | 26 | | | 36 | | | (28) | % | | 87 | | | 105 | | | (17) | % | ENBREL — Canada | 19 | | | 30 | | | (37) | % | |
Total ENBREL | Total ENBREL | $ | 1,289 | | | $ | 1,325 | | | (3) | % | | $ | 3,357 | | | $ | 3,724 | | | (10) | % | Total ENBREL | $ | 862 | | | $ | 924 | | | (7) | % | |
The decrease in ENBREL sales for the three months ended September 30, 2021, was driven by a decline in unit demand, unfavorable changes in inventory and lower net selling price, partially offset by favorable changes to estimated sales deductions. The decrease in ENBREL for the nine months ended September 30, 2021,March 31, 2022, was driven by declines in net selling price and unit demand. For the remainder of 2021, we expect the trend of net selling price declines to continue compared with the prior year.unfavorable changes in inventory.
We are involvedProlia
Total Prolia sales by geographic region were as follows (dollar amounts in patentmillions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Prolia — U.S. | $ | 582 | | | $ | 501 | | | 16 | % | | | | | | |
Prolia — ROW | 270 | | | 257 | | | 5 | % | | | | | | |
Total Prolia | $ | 852 | | | $ | 758 | | | 12 | % | | | | | | |
The increase in global Proliasales for the three months ended March 31, 2022, was driven by higher unit demand and net selling price.
XGEVA
Total XGEVA sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
XGEVA — U.S. | $ | 368 | | | $ | 334 | | | 10 | % | | | | | | |
XGEVA — ROW | 134 | | | 134 | | | — | % | | | | | | |
Total XGEVA | $ | 502 | | | $ | 468 | | | 7 | % | | | | | | |
The increase in global XGEVAsales for the three months ended March 31, 2022, was driven by favorable changes to estimated sales deductions and higher net selling price partially offset by lower unit demand.
Otezla
Total Otezla sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Otezla — U.S. | $ | 350 | | | $ | 366 | | | (4) | % | | | | | | |
Otezla — ROW | 101 | | | 110 | | | (8) | % | | | | | | |
Total Otezla | $ | 451 | | | $ | 476 | | | (5) | % | | | | | | |
The decrease in global Otezla sales for the three months ended March 31, 2022, was primarily driven by lower net selling price and unfavorable changes in inventory, partially offset by higher unit demand.
For a discussion of litigation with a company seekingrelated to market its FDA-approved biosimilar version of ENBREL. See Otezla, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements2021.
Aranesp
Total Aranesp sales by geographic region were as follows (dollar amounts in our Quarterly Report on Form 10-Qmillions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Aranesp — U.S. | $ | 137 | | | $ | 125 | | | 10 | % | | | | | | |
Aranesp — ROW | 221 | | | 230 | | | (4) | % | | | | | | |
Total Aranesp | $ | 358 | | | $ | 355 | | | 1 | % | | | | | | |
The increase in global Aranesp sales for the periodthree months ended June 30, 2021. Companies with approvedMarch 31, 2022, was driven by favorable changes to estimated sales deductions, partially offset by lower net selling price due to competition.
Aranesp continues to face competition from a long-acting ESA andalso faces competition from biosimilar versions of ENBREL may seekEPOGEN, which will continue to enterimpact sales in the U.S. market if we are not ultimately successful in our litigations, or even earlier. Other companies are also developing proposed biosimilar versions of ENBREL.future.
Prolia®Neulasta
Total Prolia®Neulasta sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Prolia® — U.S. | $ | 530 | | | $ | 478 | | | 11 | % | | $ | 1,569 | | | $ | 1,341 | | | 17 | % |
Prolia® — ROW | 273 | | | 223 | | | 22 | % | | 806 | | | 673 | | | 20 | % |
Total Prolia® | $ | 803 | | | $ | 701 | | | 15 | % | | $ | 2,375 | | | $ | 2,014 | | | 18 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Neulasta — U.S. | $ | 304 | | | $ | 421 | | | (28) | % | | | | | | |
Neulasta — ROW | 44 | | | 61 | | | (28) | % | | | | | | |
Total Neulasta | $ | 348 | | | $ | 482 | | | (28) | % | | | | | | |
The increasedecrease in global Prolia® sales for the three and nine months ended September 30, 2021, was primarily driven by higher unit demand.
Otezla®
Total Otezla®Neulasta sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Otezla® — U.S. | $ | 495 | | | $ | 439 | | | 13 | % | | $ | 1,284 | | | $ | 1,280 | | | — | % |
Otezla® — ROW | 114 | | | 99 | | | 15 | % | | 335 | | | 298 | | | 12 | % |
Total Otezla® | $ | 609 | | | $ | 538 | | | 13 | % | | $ | 1,619 | | | $ | 1,578 | | | 3 | % |
The increase in global Otezla®sales for the three months ended September 30, 2021, was primarily driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price. The increase in global Otezla® sales for the nine months ended September 30, 2021,March 31, 2022, was driven by higher unit demand, partially offset by lower net selling price.price and unit demand. Increased competition as a result of biosimilar versions of Neulasta has had and will continue to have a significant adverse impact on brand sales, including accelerating net price erosion and lower unit demand. We also expect other biosimilar versions, including biosimilars that will use an on-body injector that would compete with our Onpro injector, to be approved in the future.
ForFor a discussion of litigationongoing patent litigations related to Otezla®,biosimilars, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; Notes 122021 and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021, respectively; and Note 14, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.statements.
XGEVA®Repatha
Total XGEVA®Repatha sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
XGEVA® — U.S. | $ | 372 | | | $ | 363 | | | 2 | % | | $ | 1,061 | | | $ | 1,036 | | | 2 | % |
XGEVA® — ROW | 145 | | | 118 | | | 23 | % | | 412 | | | 361 | | | 14 | % |
Total XGEVA® | $ | 517 | | | $ | 481 | | | 7 | % | | $ | 1,473 | | | $ | 1,397 | | | 5 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Repatha — U.S. | $ | 165 | | | $ | 139 | | | 19 | % | | | | | | |
Repatha — ROW | 164 | | | 147 | | | 12 | % | | | | | | |
Total Repatha | $ | 329 | | | $ | 286 | | | 15 | % | | | | | | |
The increase in global XGEVA® Repatha sales for the three and nine months ended September 30, 2021,March 31, 2022, was driven by higher unit demand, partially offset by lower net selling price.
Neulasta®
Total Neulasta® sales by geographic region were as follows (dollar amounts Contracting changes to improve Medicare Part D and commercial patient access resulted in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Neulasta® — U.S. | $ | 360 | | | $ | 484 | | | (26) | % | | $ | 1,215 | | | $ | 1,538 | | | (21) | % |
Neulasta® — ROW | 55 | | | 71 | | | (23) | % | | 168 | | | 219 | | | (23) | % |
Total Neulasta® | $ | 415 | | | $ | 555 | | | (25) | % | | $ | 1,383 | | | $ | 1,757 | | | (21) | % |
Thethe decrease in global Neulasta® sales for the three months ended September 30, 2021, was primarily driven by the impact of biosimilar competition onto net selling price and unit demand. The decrease in global Neulasta® sales for the nine months ended September 30, 2021, was driven by the impact of biosimilar competition on net selling price and unit demand, partially offset by favorable changes to estimated sales deductions. Increased competition in the United States and Europe as a result of biosimilar versions of Neulasta® has had and will continue to have a significant adverse impact on brand sales, including additional net price erosion and lower unit demand. We also expect other biosimilar versions to be approved in the future.price.
For a discussion of ongoing patent litigationslitigation related to biosimilars,Repatha, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; Notes 122021 and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021, respectively; and Note 14, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.statements.
KYPROLIS
Total Aranesp®KYPROLIS sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Aranesp® — U.S. | $ | 149 | | | $ | 158 | | | (6) | % | | $ | 409 | | | $ | 489 | | | (16) | % |
Aranesp® — ROW | 247 | | | 226 | | | 9 | % | | 709 | | | 704 | | | 1 | % |
Total Aranesp® | $ | 396 | | | $ | 384 | | | 3 | % | | $ | 1,118 | | | $ | 1,193 | | | (6) | % |
The increase in global Aranesp® sales for the three months ended September 30, 2021, was driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price due to competition. The decrease in global Aranesp® sales for the nine months ended September 30, 2021, was primarily driven by lower net selling price due to competition.
Aranesp® continues to face competition from a long-acting erythropoiesis-stimulating agent (ESA) andalso faces competition from a biosimilar version of EPOGEN®, which will continue to impact sales in the future.
Repatha®
Total Repatha® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Repatha® — U.S. | $ | 139 | | | $ | 92 | | | 51 | % | | $ | 421 | | | $ | 331 | | | 27 | % |
Repatha® — ROW | 133 | | | 113 | | | 18 | % | | 423 | | | 303 | | | 40 | % |
Total Repatha® | $ | 272 | | | $ | 205 | | | 33 | % | | $ | 844 | | | $ | 634 | | | 33 | % |
The increase in global Repatha® sales for the three and nine months ended September 30, 2021, was primarily driven by higher unit demand, partially offset by lower net selling price.
For a discussion of ongoing litigation related to Repatha®, see Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; Notes 12 and 13, Contingencies and commitments, to the condensed consolidated financial statements for the periods ended March 31, 2021 and June 30, 2021, respectively; and Note 14, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.
KYPROLIS®
Total KYPROLIS® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
KYPROLIS® — U.S. | $ | 198 | | | $ | 173 | | | 14 | % | | $ | 547 | | | $ | 527 | | | 4 | % |
KYPROLIS® — ROW | 95 | | | 87 | | | 9 | % | | 277 | | | 266 | | | 4 | % |
Total KYPROLIS® | $ | 293 | | | $ | 260 | | | 13 | % | | $ | 824 | | | $ | 793 | | | 4 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
KYPROLIS — U.S. | $ | 196 | | | $ | 159 | | | 23 | % | | | | | | |
KYPROLIS — ROW | 91 | | | 92 | | | (1) | % | | | | | | |
Total KYPROLIS | $ | 287 | | | $ | 251 | | | 14 | % | | | | | | |
The increase in global KYPROLIS® sales for the three and nine months ended September 30, 2021,March 31, 2022, was primarily driven by higher unit demand.
We are engaged in litigation with two companies that are challenging certain of our patents related to KYPROLIS® and that are seeking to market generic carfilzomib products. Separately, we have entered into confidential settlement agreements with other companies developing generic carfilzomib products, and the court has entered consent judgments enjoining those companies from infringing certain of our patents, subject to terms of the confidential settlement agreements. See Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; and Notes 12 and 13, Contingencies and commitments, to the condensed consolidated financial statements for the periods ended March 31, 2021 and June 30, 2021, respectively. The FDA has reported that it has granted tentative or final approval of ANDAs for generic carfilzomib products filed by a number of companies. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch-WaxmanHatch–Waxman Act and any applicable settlement agreements between us and certain companies that seek to develop generic carfilzomib products.
Nplate
Total Nplate sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
Nplate — U.S. | $ | 156 | | | $ | 112 | | | 39 | % | | | | | | |
Nplate — ROW | 110 | | | 115 | | | (4) | % | | | | | | |
Total Nplate | $ | 266 | | | $ | 227 | | | 17 | % | | | | | | |
The increase in global Nplate sales for the parties.three months ended March 31, 2022, was driven by higher unit demand and favorable changes to estimated sales deductions.
Other products
Other product sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended September 30, | | | | Nine months ended September 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
MVASI® — U.S. | $ | 187 | | | $ | 185 | | | 1 | % | | $ | 617 | | | $ | 442 | | | 40 | % |
MVASI® — ROW | 87 | | | 46 | | | 89 | % | | 245 | | | 76 | | | * |
Nplate® — U.S. | 156 | | | 118 | | | 32 | % | | 404 | | | 352 | | | 15 | % |
Nplate® — ROW | 117 | | | 94 | | | 24 | % | | 341 | | | 271 | | | 26 | % |
Vectibix® — U.S. | 84 | | | 90 | | | (7) | % | | 255 | | | 249 | | | 2 | % |
Vectibix®— ROW | 116 | | | 103 | | | 13 | % | | 375 | | | 341 | | | 10 | % |
KANJINTI® — U.S. | 92 | | | 149 | | | (38) | % | | 354 | | | 346 | | | 2 | % |
KANJINTI® — ROW | 24 | | | 18 | | | 33 | % | | 79 | | | 63 | | | 25 | % |
EPOGEN® — U.S. | 138 | | | 149 | | | (7) | % | | 393 | | | 465 | | | (15) | % |
EVENITY® — U.S. | 94 | | | 54 | | | 74 | % | | 230 | | | 131 | | | 76 | % |
EVENITY®— ROW | 55 | | | 5 | | | * | | 157 | | | 129 | | | 22 | % |
BLINCYTO® — U.S. | 74 | | | 54 | | | 37 | % | | 201 | | | 167 | | | 20 | % |
BLINCYTO® — ROW | 51 | | | 35 | | | 46 | % | | 139 | | | 109 | | | 28 | % |
AMGEVITA™ — ROW | 111 | | | 80 | | | 39 | % | | 324 | | | 228 | | | 42 | % |
Aimovig® — U.S. | 77 | | | 105 | | | (27) | % | | 225 | | | 274 | | | (18) | % |
Aimovig® — ROW | 2 | | | — | | | NM | | 2 | | | — | | | NM |
Parsabiv® — U.S. | 24 | | | 156 | | | (85) | % | | 107 | | | 462 | | | (77) | % |
Parsabiv® — ROW | 37 | | | 27 | | | 37 | % | | 104 | | | 82 | | | 27 | % |
NEUPOGEN® — U.S. | 32 | | | 44 | | | (27) | % | | 86 | | | 117 | | | (26) | % |
NEUPOGEN® — ROW | 20 | | | 21 | | | (5) | % | | 51 | | | 62 | | | (18) | % |
Sensipar® — U.S. | — | | | 7 | | | (100) | % | | 4 | | | 81 | | | (95) | % |
Sensipar®/Mimpara™ — ROW | 19 | | | 32 | | | (41) | % | | 62 | | | 162 | | | (62) | % |
LUMAKRAS® — U.S. | 33 | | | — | | | NM | | 42 | | | — | | | NM |
LUMYKRAS™ — ROW | 3 | | | — | | | NM | | 3 | | | — | | | NM |
Other — U.S. | 61 | | | 31 | | | 97 | % | | 141 | | | 78 | | | 81 | % |
Other — ROW | 32 | | | 52 | | | (38) | % | | 92 | | | 129 | | | (29) | % |
Total other products | $ | 1,726 | | | $ | 1,655 | | | 4 | % | | $ | 5,033 | | | $ | 4,816 | | | 5 | % |
Total U.S. — other products | $ | 1,052 | | | $ | 1,142 | | | (8) | % | | $ | 3,059 | | | $ | 3,164 | | | (3) | % |
Total ROW — other products | 674 | | | 513 | | | 31 | % | | 1,974 | | | 1,652 | | | 19 | % |
Total other products | $ | 1,726 | | | $ | 1,655 | | | 4 | % | | $ | 5,033 | | | $ | 4,816 | | | 5 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | | | |
| 2022 | | 2021 | | Change | | | | | | |
MVASI — U.S. | $ | 168 | | | $ | 224 | | | (25) | % | | | | | | |
MVASI — ROW | 76 | | | 70 | | | 9 | % | | | | | | |
Vectibix — U.S. | 85 | | | 79 | | | 8 | % | | | | | | |
Vectibix— ROW | 116 | | | 112 | | | 4 | % | | | | | | |
EVENITY — U.S. | 110 | | | 57 | | | 93 | % | | | | | | |
EVENITY— ROW | 60 | | | 50 | | | 20 | % | | | | | | |
BLINCYTO — U.S. | 79 | | | 65 | | | 22 | % | | | | | | |
BLINCYTO — ROW | 59 | | | 42 | | | 40 | % | | | | | | |
EPOGEN — U.S. | 120 | | | 125 | | | (4) | % | | | | | | |
AMGEVITA — ROW | 108 | | | 106 | | | 2 | % | | | | | | |
Aimovig — U.S. | 98 | | | 66 | | | 48 | % | | | | | | |
Aimovig — ROW | 3 | | | — | | | NA | | | | | | |
KANJINTI — U.S. | 80 | | | 130 | | | (38) | % | | | | | | |
KANJINTI — ROW | 16 | | | 31 | | | (48) | % | | | | | | |
Parsabiv — U.S. | 57 | | | 46 | | | 24 | % | | | | | | |
Parsabiv — ROW | 29 | | | 33 | | | (12) | % | | | | | | |
LUMAKRAS — U.S. | 48 | | | — | | | NA | | | | | | |
LUMYKRAS — ROW | 14 | | | — | | | NA | | | | | | |
NEUPOGEN — U.S. | 23 | | | 18 | | | 28 | % | | | | | | |
NEUPOGEN — ROW | 15 | | | 16 | | | (6) | % | | | | | | |
Sensipar — U.S. | 4 | | | — | | | NA | | | | | | |
Sensipar/Mimpara — ROW | 16 | | | 23 | | | (30) | % | | | | | | |
Other — U.S. | 64 | | | 42 | | | 52 | % | | | | | | |
Other — ROW | 28 | | | 30 | | | (7) | % | | | | | | |
Total other products | $ | 1,476 | | | $ | 1,365 | | | 8 | % | | | | | | |
Total U.S. — other products | $ | 936 | | | $ | 852 | | | 10 | % | | | | | | |
Total ROW — other products | 540 | | | 513 | | | 5 | % | | | | | | |
Total other products | $ | 1,476 | | | $ | 1,365 | | | 8 | % | | | | | | |
___________
NMNA - Not meaningfulnot applicable
* - Change in excess of 100%
Operating expenses
Operating expenses were as follows (dollar amounts in millions):
| | | Three months ended September 30, | | Nine months ended September 30, | | | Three months ended March 31, | | |
| | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change | | 2022 | | 2021 | | Change | |
Operating expenses: | Operating expenses: | | | | | | | | | | | | Operating expenses: | | | | | | |
Cost of sales | Cost of sales | $ | 1,609 | | | $ | 1,561 | | | 3 | % | | $ | 4,736 | | | $ | 4,562 | | | 4 | % | Cost of sales | $ | 1,561 | | | $ | 1,490 | | | 5 | % | |
% of product sales | % of product sales | 25.5 | % | | 25.6 | % | | 26.3 | % | | 25.5 | % | | % of product sales | 27.2 | % | | 26.6 | % | | |
% of total revenues | % of total revenues | 24.0 | % | | 24.3 | % | | 24.8 | % | | 24.3 | % | | % of total revenues | 25.0 | % | | 25.2 | % | | |
Research and development | Research and development | $ | 1,422 | | | $ | 1,062 | | | 34 | % | | $ | 3,471 | | | $ | 2,978 | | | 17 | % | Research and development | $ | 959 | | | $ | 967 | | | (1) | % | |
% of product sales | % of product sales | 22.5 | % | | 17.4 | % | | 19.3 | % | | 16.6 | % | | % of product sales | 16.7 | % | | 17.3 | % | | |
% of total revenues | % of total revenues | 21.2 | % | | 16.5 | % | | 18.1 | % | | 15.8 | % | | % of total revenues | 15.4 | % | | 16.4 | % | | |
Acquired in-process research and development | $ | — | | | $ | — | | | — | % | | $ | 1,505 | | | $ | — | | | NM | |
% of product sales | — | % | | — | % | | 8.3 | % | | — | % | | |
% of total revenues | — | % | | — | % | | 7.9 | % | | — | % | | |
| Selling, general and administrative | Selling, general and administrative | $ | 1,305 | | | $ | 1,346 | | | (3) | % | | $ | 3,943 | | | $ | 3,957 | | | — | % | Selling, general and administrative | $ | 1,228 | | | $ | 1,254 | | | (2) | % | |
% of product sales | % of product sales | 20.6 | % | | 22.1 | % | | 21.9 | % | | 22.1 | % | | % of product sales | 21.4 | % | | 22.4 | % | | |
% of total revenues | % of total revenues | 19.5 | % | | 21.0 | % | | 20.6 | % | | 21.1 | % | | % of total revenues | 19.7 | % | | 21.3 | % | | |
Other | Other | $ | (8) | | | $ | 1 | | | * | | $ | 143 | | | $ | 162 | | | (12) | % | Other | $ | (10) | | | $ | 61 | | | * | |
Total operating expenses | | Total operating expenses | $ | 3,738 | | | $ | 3,772 | | | (1) | % | |
___________
NM - Not meaningful
* - Change in excess of 100%
Cost of sales
Cost of sales decreased to 24.0%25.0% of total revenues for the three months ended September 30, 2021,March 31, 2022, primarily driven by the COVID-19 antibody profit share agreement and lower amortization expense from acquisition-related assets, offset by unfavorable product mix.
Cost of sales increased to 24.8% of total revenues for the nine months ended September 30, 2021, primarily driven by unfavorable product mix, partially offset by lower amortization expense from acquisition-related assets.higher manufacturing costs and increased royalties and profit share.
Research and development
The increasedecrease in R&D expense for the three months ended September 30, 2021,March 31, 2022, was driven by a licensing-related upfront payment to KKC, partially offset by lower late-stagemarketed product support for existing programs.
The increase in R&D expense for the nine months ended September 30, 2021, was primarily driven by a licensing-related upfront payment to KKC and higher research and early pipeline spend, which included a business development acquisition in the three months ended March 31, 2021, partially offset by lowerhigher late-stage support for existing programs.
Acquired in-process research and development
Acquired IPR&D expense for the nine months ended September 30, 2021, is related to the bemarituzumab program acquired as part of the Five Prime acquisition.spend.
Selling, general and administrative
The decrease in Selling, general and administrative (SG&A)SG&A expense for the three months ended September 30, 2021,March 31, 2022, was primarily driven by lower spend in general and administrative activities.
The decrease in SG&A expense for the nine months ended September 30, 2021, was primarily driven by lower spend in general and administrative activities and favorable adjustments to estimated U.S. healthcare reform federal excise fees, partially offset by higher marketed-product support and investment in new launches.
Other
Other operating expenses for the three months ended September 30, 2021,March 31, 2022, consisted primarily of changes in the fair values of contingent consideration liabilities.an IPR&D asset adjustment. Other operating expenses for the ninethree months ended September 30,March 31, 2021, consisted primarily of expenses related to cost savings initiatives.
Other operating expenses for the nine months ended September 30, 2020, consisted of legal settlement expenses.
Nonoperating expense/income and income taxes
Nonoperating expense/income and income taxes were as follows (dollar amounts in millions):
| | | Three months ended September 30, | | Nine months ended September 30, | | Three months ended March 31, | |
| | 2021 | | 2020 | | 2021 | | 2020 | | 2022 | | 2021 | |
Interest expense, net | Interest expense, net | $ | (296) | | | $ | (302) | | | $ | (862) | | | $ | (944) | | Interest expense, net | $ | (295) | | | $ | (285) | | |
Other income, net | $ | 73 | | | $ | 55 | | | $ | 97 | | | $ | 69 | | |
Other (expense) income, net | | Other (expense) income, net | $ | (530) | | | $ | 13 | | |
Provision for income taxes | Provision for income taxes | $ | 271 | | | $ | 185 | | | $ | 576 | | | $ | 607 | | Provision for income taxes | $ | 199 | | | $ | 211 | | |
Effective tax rate | Effective tax rate | 12.6 | % | | 8.4 | % | | 12.6 | % | | 9.7 | % | Effective tax rate | 11.9 | % | | 11.4 | % | |
Interest expense, net
The decreaseincrease in Interest expense, net, for the three months ended September 30, 2021,March 31, 2022, was primarily due to lowerhigher overall debt outstanding and higher LIBOR rates in the current year period on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset by higher overall debt outstanding in the current year period.swaps.
Other (expense) income, net
The decrease in Interest expense,Other (expense) income, net, for the ninethree months ended September 30, 2021,March 31, 2022, was primarily due to net costs associated with the early retirement of debt in the first quarter of the prior year and lower LIBOR rates in the current year period on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset by higher overall debt outstanding in the current year period.
Other income, net
The increase in Other income, net, for the three and nine months ended September 30, 2021, was primarily due to net gainslosses recognized on our strategic equity investments partially offset by higher losses in connectionthe current year compared with our BeiGene investment.net gains recognized in the prior year.
Income taxes
The increase in our effective tax rate for the three and nine months ended September 30, 2021,March 31, 2022, was primarily due to the non-deductible IPR&D expense arising from the acquisition of Five Prime and priorcurrent year favorablenet unfavorable items partiallycompared to last year, offset by a changechanges in earnings mix.
The Administration proposed and Congress areis considering significant changes to existing tax law, including an increase in the corporate tax rate and the tax rate on foreign earnings.law. These changes, if enacted, could substantially increase U.S. taxation of our operations both in and outside the United States, includingtaxes we pay to the U.S. territory of Puerto Rico. In addition,government. Further, the Organisation for Economic Co-operation and Development (OECD)OECD recently reached agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, this agreement could result in tax increases in both the United States and foreign jurisdictions. The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning in 2023, which will increase our U.S. tax liability. The U.S. territory of Puerto Rico is considering changes to its tax system that may minimize or eliminate this impact, but the outcome of such potential changes is uncertain. Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, including the potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.
In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. As previously reported, we were unable to reach resolution with the IRS appeals office.office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for 2010, 2011 and 2012 that we received in May and July 2021. The duplicate Notices2021, which seek to increase our U.S. taxable income for 2010-2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for 2010-2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In any event, we firmly believe that the IRS’s positions in the Notices are without merit, and we will vigorously contest the Notices through the judicial process.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreedisagreed with the proposed adjustments and calculations and have been pursuingpursued resolution with the IRS administrative appeals office. Asoffice but were unable to reach resolution. In April 2022, we received a consequenceNotice that seeks to increase our U.S. taxable income for 2013-2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for 2013-2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.
We firmly believe that the IRS positions set forth in the 2010-2012 and 2013-2015 Notices are without merit. We are contesting the 2010-2012 Notices through the judicial process, and we expect to file a Petition in the U.S. Tax Court to contest the 2013-2015 Notice through the judicial process. We will seek consolidation of the two periods into one case in Tax Court litigation for the 2010-2012 period, the IRS administrative appeals office recently informed us that it does not plan to engage in discussions at this time regarding the allocation of profits between our entities in the United States and the U.S. territory of Puerto Rico for the 2013-2015 period. Court.
We are also currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination2018 and by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued as noted above and could have a material adverse impact on our condensed consolidated financial statements.
We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
SeePart II, Item 1A, Risk Factors—The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability, and Note 4, Income taxes, to the condensed consolidated financial statements for further discussion.discussion.
Financial condition, liquidity and capital resources
Selected financial data were as follows (in millions):
| | | September 30, 2021 | | December 31, 2020 | | March 31, 2022 | | December 31, 2021 |
Cash, cash equivalents and marketable securities | Cash, cash equivalents and marketable securities | $ | 12,921 | | | $ | 10,647 | | Cash, cash equivalents and marketable securities | $ | 6,544 | | | $ | 8,037 | |
Total assets | Total assets | $ | 64,993 | | | $ | 62,948 | | Total assets | $ | 59,196 | | | $ | 61,165 | |
Current portion of long-term debt | Current portion of long-term debt | $ | 4,288 | | | $ | 91 | | Current portion of long-term debt | $ | 844 | | | $ | 87 | |
Long-term debt | Long-term debt | $ | 33,291 | | | $ | 32,895 | | Long-term debt | $ | 36,010 | | | $ | 33,222 | |
Stockholders’ equity | Stockholders’ equity | $ | 8,217 | | | $ | 9,409 | | Stockholders’ equity | $ | 916 | | | $ | 6,700 | |
Cash, cash equivalents and marketable securities
Our balance of cash, cash equivalents and marketable securities was $12.9$6.5 billion at September 30, 2021.March 31, 2022. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Capital allocation
Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), payment of dividends, stock repurchases and repayment of debt.
We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company’s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, ASRs and market transactions.
In JulyDecember 2021, March 2021 and December 2020, the Board of Directors declared a quarterly cash dividend of $1.76$1.94 per share of common stock which were paid on September 8, 2021, June 8, 2021 and March 8, 2021, respectively,for the first quarter of 2022, an increase of 10% over the quarterly cash dividendfor this period, which was paid in each quarter in 2020.on March 8, 2022. In October 2021,March 2022, the Board of Directors declared a quarterly cash dividend of $1.76$1.94 per share of common stock, which will be paid on DecemberJune 8, 2021.2022.
We also returned capital to stockholders through our stock repurchase program. During the ninethree months ended September 30, 2021,March 31, 2022, we executed trades to repurchase $3.5$5.4 billion of common stock.stock, including $5.1 billion of an initial purchase under the ASR agreements described below. As of September 30, 2021, $2.9March 31, 2022, $4.6 billion of authorization remained available under our stock repurchase program.
In October 2021,February 2022, we entered into ASR agreements under which we paid an aggregate amount of $6.0 billion to the BoardDealers and retired an initial 23.3 million shares of Directors increasedcommon stock. Approximately $0.9 billion of stock remains to be delivered by the amount authorizedDealers pending final settlement, which will be based on the daily volume-weighted average stock price of our common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional shares of common stock to us, or under certain circumstances, we may be required to deliver shares of common stock or to make a cash payment, at our stock repurchase program by an additional $4.5 billion.
election, to the Dealers.As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of September 30, 2021March 31, 2022 and December 31, 2020.2021. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our continuing profitability and strong financial position.
We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, to meet capital expenditure and debt service requirements, to fund our plans to pay dividends and repurchase stock and to fulfill other business initiatives we expectplan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, equity markets and borrowings (includingthrough commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets).markets and equity markets. See our Annual Report on Form 10-K for the year ended December 31, 2020,2021, Part I, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of September 30, 2021.March 31, 2022.
Cash flows
Our summarized cash flow activity was as follows (in millions):
| | | Nine months ended September 30, | | Three months ended March 31, |
| | 2021 | | 2020 | | 2022 | | 2021 |
Net cash provided by operating activities | Net cash provided by operating activities | $ | 6,453 | | | $ | 8,344 | | Net cash provided by operating activities | $ | 2,164 | | | $ | 2,104 | |
Net cash provided by (used in) investing activities | $ | 963 | | | $ | (4,017) | | |
Net cash used in investing activities | | Net cash used in investing activities | $ | (111) | | | $ | (319) | |
Net cash used in financing activities | Net cash used in financing activities | $ | (1,713) | | | $ | (1,277) | | Net cash used in financing activities | $ | (3,514) | | | $ | (1,939) | |
Operating
Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities during the ninethree months ended September 30, 2021, decreasedMarch 31, 2022, increased primarily due to (i) the monetization of interest rate swaps in the prior year, (ii) a difference in the timing of payments to tax authorities and sales deductions paid to customers, (iii) lower Nethigher net income, after adjustments for noncash items, and (iv) the timing of collections from customers.
Investing
Cash provided by investing activities during the nine months ended September 30, 2021, was primarily due to net cash inflows related to marketable securities of $3.4 billion, partially offset by the acquisitionimpact of Five Prime for $1.6 billion, net of cash acquired, andworking capital expenditures of $593 million. items.
Investing
Cash used in investing activities during the ninethree months ended September 30, 2020,March 31, 2022, was primarily due to our $3.2 billion$190 million of equity investments,capital expenditures, partially offset by proceeds from sales of property, plant and equipment. Cash used in investing activities during the three months ended March 31, 2021, was primarily BeiGene,due to cash outflows related to capital expenditures of $435$166 million and net cash outflowsactivity related to marketable securities of $394$74 million. We currently estimate 20212022 spending on capital projects to be approximately $900$950 million.
Financing
Cash used in financing activities during the ninethree months ended September 30, 2021,March 31, 2022, was primarily due to payments to repurchase our common stock of $3.5$6.4 billion, including amounts paid under the ASR agreements discussed above, and the payment of dividends of $3.0$1.1 billion, partially offset by proceeds from the issuance of debt of $4.9$4.0 billion. Cash used in financing activities during the ninethree months ended September 30, 2020,March 31, 2021, was primarily due to the payment of dividends of $2.8$1.0 billion and payments to repurchase our common stock of $2.3 billion, partially offset by proceeds from the issuance of debt, net of repayments, of $3.9 billion.$871 million. See Note 10,9, Financing arrangements, and Note 11,10, Stockholders’ equity, to the condensed consolidated financial statements for further discussion.
Critical accounting policiesAccounting Policies and Estimates
The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies and estimates is presented in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2020.2021.
| | | | | |
Item 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Information about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2020,2021, and is incorporated herein by reference. Except as discussed below, thereThere were no material changes during the ninethree months ended September 30, 2021,March 31, 2022, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2020.
Interest rate sensitive financial instruments
To achieve a desired mix of fixed and floating interest rate debt, we entered into additional interest rate swap contracts with an aggregate notional amount of $1.5 billion during the three months ended June 30, 2021. As of September 30, 2021, an aggregate notional amount of $7.4 billion of interest rate swap contracts was outstanding. These interest rate swap contracts effectively converted a fixed-interest-rate coupon to a floating-rate LIBOR-based coupon over the life of the respective notes. A hypothetical 100-basis-point increase in interest rates relative to interest rates at September 30, 2021, would have resulted in a reduction in fair value of approximately $370 million on our interest rate swap contracts on that date. The analysis of the interest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on the related fair value of debt that these interest-rate-sensitive instruments were designed to offset.
| | | | | |
Item 4. | CONTROLS AND PROCEDURES |
We maintain “disclosure controls and procedures,” as such term is defined under the Securities Exchange Act Rule 13a-15(e) that are designed to ensure that information required to be disclosed in Amgen’s Exchange Act reports gets recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information gets accumulated and communicated to Amgen’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to facilitate timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen’s management necessarily was required to apply its judgment in evaluating the cost–benefit relationship of possible controls and procedures. We carried out an evaluation under the supervision and with the participation of our management, including Amgen’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen’s disclosure controls and procedures. Based on their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2021.March 31, 2022.
Management determined that as of September 30, 2021,March 31, 2022, no changes in our internal control over financial reporting had occurred during the fiscal quarter then ended that materially affected or are reasonably likely to materially affect our internal control over financial reporting.
PART II — OTHER INFORMATION
See Notes 12,Note 13, and 14, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly ReportsReport on Form 10-Q for the periodsperiod ended March 31, 2021, June 30, 2021 and September 30, 2021, respectively,2022, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Note 19, Contingencies and commitments, to the consolidated financial statements in Part IV of our Annual Report on Form 10-K for the year ended December 31, 2020.2021.
This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.
Below we provide, in supplemental form, the material changes to our risk factors that occurred during the past quarter. Our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2020,2021, provide additional disclosure for these supplemental risks, as well as other risks to our Company, and are incorporated herein by reference.
RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS, INCLUDING DURING THE COVID-19 PANDEMIC
The COVID-19 pandemic,Our sales and operations are subject to the effort to mitigate the spreadrisks of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales,doing business and results of operations.internationally, including in emerging markets.
The novel coronavirus identifiedAs we continue our expansion efforts in late 2019, SARS-CoV-2, which causesemerging markets around the disease knownworld, through acquisitions and licensing transactions as COVID-19,well as through the development and introduction, both independently and through collaborations such as our collaboration with BeiGene, of our products in new markets, we face numerous risks to our business. There is an ongoingno guarantee that our efforts and strategies to expand sales in emerging markets will succeed. Our international business, including in China and emerging market countries, may be especially vulnerable to periods of global pandemic that has resulted in public and governmental efforts to contain or slowlocal political, legal, regulatory and financial instability, including issues of geopolitical relations, the spreadimposition of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implementedinternational sanctions in response to certain state actions and/or sovereign debt issues. Further, in the pandemic are adversely affecting,first quarter of 2022, the Asia Pacific region has also experienced a surge of COVID-19 infections, resulting in the activation of strict containment measures in certain countries in that region. If relations between the United States and are expected to continue to adversely affect,other governments deteriorate, our business (includingand investments in such markets may also be adversely affected. We may also be required to increase our R&D, clinical trials,reliance on third-party agents and unfamiliar operations manufacturing, supply chains, distribution systems, product development and sales activities), the business activities of our suppliers, customers, third-party payers and our patients.arrangements including those previously utilized by companies we partner with or acquire in emerging markets. See our Annual Report on Form 10-K for the year ended December 31, 2020,2021, Part I, Item 1A. Risk Factors—The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations;see also Our current products and products in development cannot be sold without regulatory approval;and see also We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications. DueOur expansion efforts in China and emerging markets around the world are dependent upon the establishment of an environment that is predictable, navigable and supportive of biopharmaceutical innovation, sustained access for our products and predictable pricing controls. For example, China continues to strengthen regulations on the collection, use and transmission of Chinese human genetic resources, and has expanded regulations on the conduct of biotechnology R&D activities in China. Our applications to the pandemicHGRAC seeking approval to conduct clinical trials in China are delayed pending further guidance from HGRAC. Additionally, on March 25, 2022, BeiGene disclosed in a SEC filing its engagement of a U.S.-based independent registered public accounting firm for the fiscal year ending December 31, 2022 in response to the requirement that foreign companies provide access to their audit information to U.S. authorities. Our international operations and these measuresbusiness may also be subject to less protective intellectual property or other applicable laws, diverse data privacy and their effects, we have experienced,protection requirements, changing tax laws and expect to continue to experience, unpredictable reductions in demand for certain of our products, exacerbated by COVID-19 surges resulting in repeated shutdowns and/tariffs, trade restrictions or disruptions in certain geographies.
Federal, state and local, and international governmental policies and initiativesother barriers designed to reduce the transmission of COVID-19 also have resultedprotect industry in the cancellation home country against foreign competition, far-reaching antibribery and anticorruption laws and regulations and/or delay of diagnostic, elective, specialtyevolving legal and other procedures and appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. For example, a recent NPR/Harvard poll found that, with hospitals crowded from COVID-19, one in five U.S. households has had to delay care for serious illnesses in the past few months. These measures and challenges will likely continue to varying degrees for the duration of the pandemic and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia® requires administration by a healthcare provider in doctors’ offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia® instructs healthcare professionals who discontinue Prolia® to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive orregulatory environments.
therapies that do not require administrationIn response to the ongoing armed conflict in a hospital setting, potentially adversely affecting certain of our products. Also, new patients have been,Ukraine, the U.S. government, numerous state governments, the EU and are expected to continue to be, less likely to be diagnosed and/or to start therapeutics during the pandemic, and these effects, together with the lower treatment rates during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decreaseother countries in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact ourconduct business for the remainderhave imposed a wide range of the year. Once the pandemic subsides, we anticipate there could be a backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate lower provider capacity, and this lower provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatmentseconomic sanctions that do not require administration by healthcare professionals or visits to medical facilities.
As the pandemic continues, and if conditions worsen or if the duration of the pandemic extends significantly, we expect to experience additional adverse effects on our development, operational and commercial activities, customer purchases and our collections of accounts receivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections as conditions begin to improve. There has been a resurgence in COVID-19 infections in numerous jurisdictions to date in 2021, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions, including in the United States., Europe and Asia Pacific regions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. New variants of the SARS-CoV-2 virus have emerged, including the delta variant, and have been shown to be present in many geographies, and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain their efficacy against future variants of the virus. Further, even while vaccine booster shots are available for certain patients, persistent vaccine hesitancy may result in under-vaccinated populations which may prolong the duration of the COVID-19 pandemic and continue to disrupt the availability of healthcare services to the patients we serve. Jurisdictions may implement, continue or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travelcommerce and business activity, which could significantly affect our ability to support our operationsdealings with Russia, certain regions of Ukraine and customerscertain entities and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain, and further prevent or discourage patients from participating in our clinical trials, seeking healthcare services and the administration of certain of our products. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliersindividuals. This conflict may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the United States, on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 (including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of COVID-19 antibody therapies for Eli Lilly and Company) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of, materials or components used in the development, manufacturing, distribution, or administration of our products. For example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our clinical trials has developed that we are actively monitoring and managing. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.
The COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described herein and in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020,2021, Part I, Item 1A. Risk Factors, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could materially adversely affect our business, operations and financial conditionscondition and results. For example, if a natural disaster or other potentially disruptive event occurs concurrently with the COVID-19 pandemic, such disaster or event could deplete our inventory levels and
As we could experience a disruption to our manufacturing or ability to supply our products. Further, the global pandemic has exacerbated geopolitical tensions, and some countries, such as China, may be especially vulnerable to such dynamics. If relations between the United States and China or other governments deteriorates, our business and investments in China or other such markets may also be adversely affected. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—Our sales and operationsexpand internationally, we are subject to fluctuations in foreign currency exchange rates relative to the risksU.S. dollar. While we have a program in place that is designed to reduce our exposure to foreign currency exchange rate fluctuations through foreign currency hedging arrangements, our hedging efforts do not completely offset the effect of doing business internationally, includingthese fluctuations on our revenues and earnings. In addition, we have a number of financial instruments referencing the LIBOR. On July 27, 2017, the U.K. Financial Conduct Authority, which regulates LIBOR, announced that it will no longer require banks to submit rates for the calculation of LIBOR to the LIBOR administrator after 2021, and it is anticipated that LIBOR will be completely phased out and replaced by 2023. In March 2020 and in emerging markets.
The rapid development and fluidityJanuary 2021, the FASB issued a new accounting standard to ease the financial burdens of the pandemic preclude any prediction asexpected market transition from LIBOR and other interbank offered rates to alternative reference rates. While it appears likely that Secured Overnight Financing Rate (SOFR) will be the ultimate effectreplacement reference rate adopted in the market, the specific mechanisms to replace LIBOR in our existing LIBOR-linked financial instruments have not been finalized. As such, the replacement of COVID-19 on us. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19 (including the distribution and/or availability of vaccines), and the extent to which such measures are effective, if at all, remain highly uncertain. The magnitude and degree of COVID-19’sLIBOR could have an adverse effect on our business (including our product development,
product sales, operating results and resulting cash flows) and financial condition will be driven by the severity and duration of the pandemic, the pandemic’s effect on the United States and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. If mitigation of the pandemic continues to require further shelter-in-place and shutdown orders and/market for, or restrictions on individual and/or group conduct, any adverse effects of the COVID-19 pandemic will likely grow and could be enduring and our business and financial position could be materially adversely affected.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availabilityvalue of, our information technology systems, network-connected control systems and/or our data, interrupt the operationLIBOR-linked financial instruments. See Part IV—Note 1, Summary of our business and/or affect our reputation.
To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.
Our information technology systems are highly integrated into our business, including our R&D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems makes them potentially vulnerable to breakdown or other service interruptions. Upgrades or changes to our systems or the software that we use may result in the introduction of new cybersecurity vulnerabilities and risks. Our systemsaccounting policies—Recent accounting pronouncements. We are also subject to frequent cyberattacks. As the cyber-threat landscape evolves, these attacks are growingeconomic and political uncertainties stemming from the United Kingdom’s exit from the EU, commonly referred to as “Brexit,” which occurred on January 31, 2020. While our manufacturing and packaging activities take place largely outside the United Kingdom, minimizing the need to make costly and significant changes to those operations, we have nevertheless been working to put in frequency, sophisticationplace contingency plans to attempt to mitigate the effects of Brexit on us. Overall, the legal and intensityoperational challenges of our international business operations, along with government controls, the challenges of attracting and are becoming increasingly difficult to detect. Such attacks could include the use of harmfulretaining qualified personnel and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websitesobtaining and/or the usemaintaining necessary regulatory or pricing approvals of social engineering. We have also experienced unsuccessful denial of service attacks against our network, and although such attacks did not succeed, there can be no assurance that our efforts to guard against the wide and growing variety of potential attack techniques will be successful in the future. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the European Medicines Agency (EMA)) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have amay result in material adverse effecteffects on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products in certain markets were negatively affected. In December 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development,international product sales, business and results of operationsoperations. for a discussion of the cyberattack on the EMA.
Our systems also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) resulting from attacks or lapses by employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, “hacktivists” or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors, or the public. For example, a supplier recently experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information). As required, we promptly notified the applicable state attorneys general and the individuals whose personally identifiable information was affected of this data breach at the supplier. Although the supplier data breach did not result in a material adverse effect on our business, there can be no assurance that a similar future cybersecurity incident would not result in a material adverse effect on our business or results of operations. Another vendor experienced a cyberattack and, while initially reporting that our information was not involved, the vendor subsequently informed us that the attacker had accessed limited, non-significant information. Although this breach did not have a significant
adverse effect on us, we may not receive timely reporting of future breaches.
Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services, and companies we have or may acquire face similar risks, and security breaches of their systems or service outages could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data or sensitive personal information. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products have experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Although there was no breach of our systems, each of these incidents required us to disconnect our systems from those vendors’ systems. While we were able to reconnect our systems following restoration of these vendors’ capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients.
Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.
We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the European Union’s General Data Protection Regulation, which became effective in May 2018, and the California Consumer Privacy Act of 2018 (CCPA), which became effective in January 2020, both of which provide for substantial penalties for non-compliance. The CCPA was amended in late 2020, to create the California Privacy Rights Act to create opt-in requirements for the use of sensitive personal data and the formation of a new dedicated agency for the enforcement of the law, the California Privacy Protection Agency. Since then, Virginia and Colorado both passed similar consumer privacy laws that will go into effect in 2023. Other jurisdictions where we operate continue to propose similar legislation and/or regulations with others expected to pass in 2021. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.
RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES
Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.
Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on the effectiveness, benefits and costs of similar treatments, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices. These include proposals that would allow the U.S. government to negotiate drug prices directly, limit drug reimbursement in Medicare and/or the commercial market based on a reference prices or permit importation of drugs from Canada. Additional proposals would require a rebate to the government for any price increase in excess of the Consumer Price Index for All Urban Consumers and/or to shift some of the costs of these Medicare Part D reforms to manufacturers to offset the cost. Proposals focused on drug pricing have been implemented and are likely to continue to be proposed and may be adopted and implemented in some form. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.
—Changing U.S. federal coverage and reimbursement policies and practices have affected and may continue to affect access to, pricing and sales of our products
A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1. Business—Reimbursement. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Congress has been focused on drug pricing reforms and oversight since 2018, and is ongoing. For example, in 2020, Amgen participated in House Oversight and Reform Committee hearings on drug pricing practices. Additionally, in 2019 and 2020, a number of other Congressional committees debated drug pricing reform proposals. For example, in 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries and require higher/additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives, which would, among other things, enable direct price negotiations by the federal government on certain drugs (with the maximum price paid by Medicare capped by prices derived from an international index), includes a penalty for failing to reach agreement with the government and requires that manufacturers offer these negotiated prices to other payers. Further, proposals from H.R. 3 have been incorporated into other proposed legislation, including the House’s drug pricing provisions based on H.R. 3 in the Build Back Better reconciliation bill, and proposals from H.R. 3 are also likely to be included in the version of the reconciliation bill that remains to be further debated between the House, Senate and White House. Other legislation has also contained drug pricing reforms, including the Infrastructure Investment and Jobs Act passed by the Senate in August 2021, which includes a provision that would, starting in 2023, require manufacturers to provide Medicare with rebates for certain drugs paid under Medicare Part B, and the American Rescue Plan Act of 2021, which includes a provision, to be implemented in 2024, that increases the Medicaid rebate liability for certain medicines that raise prices in excess of inflation. On November 2, 2021, Congress announced a framework for drug pricing reform that includes inflation penalties, Medicare negotiation for select drugs paid for under Parts B and D, and a Medicare Part D redesign. As of the date of this filing, this framework remains in discussion with policymakers in Congress and the Administration.
There are other outstanding proposals that have been introduced by the prior Administration that, if enacted and implemented in whole or in part, could also affect access to and sales of our products, including, but not limited to, proposals to allow importation of prescription medications from Canada or other countries and to set Medicare payment rates using international price referencing. Further, in mid-2020, the prior Administration announced a number of Executive Orders intended to reduce the cost of biopharmaceuticals for patients, including a most favored nation (MFN) policy for Medicare Parts B and D, under which the Health & Human Services (HHS) was directed to take steps to implement payment models that set Medicare purchase prices based on the lowest price available in economically comparable countries for certain Part B and Part D medicines. In September 2020, in response to the corresponding Executive Order, HHS released a final rule to allow states (or other nonfederal government entities) to submit proposals to the FDA allowing for the importation of certain nonbiologic prescription drugs from Canada. Currently, the rule is being challenged by litigation, however, should such litigation be unsuccessful and should the Secretary of HHS authorize state proposals for importation, this rule could allow the importation of Canadian versions of certain of Amgen’s products (including Otezla®), that could have a material adverse effect on Amgen’s business. Further, in November 2020, also in response to the corresponding Executive Order, HHS released an interim final rule to implement the MFN pricing approach. If implemented, the MFN rule would set the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia®, XGEVA®, KYPROLIS®, Neulasta®, Nplate®, EPOGEN® and Aranesp®) equal to the lowest adjusted price for such products of the 22 OECD nations. Lawsuits have been filed by certain trade groups challenging the implementation of this MFN rule based on, among other things, procedural defects. Late in 2020, in the case filed by the Biotechnology Innovation Organization (BIO) and others, the U.S. District Court for the Northern District of California issued a preliminary injunction preventing the rule from taking effect nationwide, pending the government’s completion of required administrative procedures. The case was subsequently stayed by the court and will remain stayed until at least November 10, 2021, when the parties will be required to submit a joint status report to the court. Another case, filed by the Pharmaceutical Research and Manufacturers of America and others in the U.S. District Court for the District of Maryland, was also stayed until either a final rule based on the MFN interim rule is published in the Federal Register, or until the court orders a lifting of the stay based on, among other things, the status of the nationwide preliminary injunction issued in the BIO case. In August 2021, Centers for Medicare & Medicaid Services (CMS) released a proposal to withdraw the MFN rule, noting, however, that the proposal to withdraw “does not reflect any judgment by HHS regarding future policy.”Notwithstanding these stays and the proposed withdrawal of the rule, the MFN rule’s approach to drug pricing and other similar approaches remain of interest. Further, despite the change in Administration, we expect continued significant focus on healthcare and similar drug pricing proposals for the foreseeable future, including proposals similar to the MFN rule or other proposals that would grant the HHS secretary the authority to negotiate drug prices directly with manufacturers. On July 9, 2021, the Administration issued an Executive Order designed to address anticompetitive behavior across multiple sectors, and for the healthcare sector, called for, among other things, more scrutiny of anticompetitive activity by the Federal Trade
Commission (FTC), emphasized the need for actions to allow for greater competition from generics and biosimilars, and called for the FDA to work with states and Indian Tribes to develop prescription drug importation programs. The Executive Order established a process and timeline for federal agencies to deliver ideas on drug pricing to the Administration, including requiring HHS to develop a comprehensive plan within 45 days to address drug pricing. Subsequently, on September 9, 2021, the HHS released a report that presented guiding principles for the Administration’s drug pricing proposals, including changes to promote competition throughout the prescription drug industry, highlighting potential legislative policies that Congress could pursue (including drug price negotiation in Medicare Parts B and D, making those negotiated prices available to commercial plans and legislation to speed the entry of biosimilar and generic drugs) and examples of potential administrative tools available to the HHS (including various testing models and enhanced focus of the FTC and the USPTO to address impediments to generic drug and biosimilar competition). Also in response to the July 9 Executive Order, the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offered training to help identify prior art, and seeking USPTO’s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents.
Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. Over the past three years, federal agencies, including the CMS, announced a number of recommendations, policies, proposals and demonstration projects addressing drug pricing. CMS is the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces and has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. CMS issued guidance to allow certain Medicare plans offered by private insurance companies to require that patients receiving Medicare Part B drugs first try a drug preferred by the plan before covering another therapy (Step Therapy) and lowered reimbursement rates for new Medicare Part B drugs. Further, HHS issued a final rule under Medicare Part D revising the regulations under the federal antikickback statute to encourage Pharmacy Benefit Managers (PBMs) to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale. While the implementation date for the rule is January 1, 2023, the rule remains subject to litigation, there are numerous logistical hurdles to overcome before it can be effectively implemented, and it is unclear how PBMs will respond and what the current Administration’s position is on the rule. Further, while the prior Administration finalized a rule (effective January 1, 2022) mandating price and cost-sharing transparency for almost all health plans and insurers in the individual and group commercial markets, the current Administration has delayed implementation of those drug price transparency provisions and has indicated that there will be future rulemaking on the issue. It is unclear how group health plans and health insurers may respond. The Administration also could develop and seek to advance a range of policy proposals that could impact U.S. federal reimbursement policy for drugs and biologics, including changes to Medicare Part B.
CMS policy changes and demonstration projects to test new care, delivery and payment models can significantly affect how drugs, including our products, are covered and reimbursed. In end-stage renal disease (ESRD), CMS uses bundled payment rates. Between 2018 and 2020, Sensipar® and Parsabiv®, our calcimimetics that are used in dialysis clinics, were eligible for temporary drug add-on payment adjustments (TDAPA) to the bundled rate. In November 2020, CMS released its final rule ending the TDAPA for calcimimetics and adjusting ESRD Prospective Payment System bundled rates on January 1, 2021 by $9.93 per dialysis treatment for calcimimetics. As a result, sales of Parsabiv® have been materially adversely affected by this rule change. Additionally, CMS created a new mandatory payment model, effective January 1, 2021, focused on encouraging greater use of home dialysis and kidney transplants for ESRD patients that could result in changes to treatment of dialysis patients, including reduction of the use of our ESAs. Further, in November 2019, CMS announced additional voluntary payment models for nephrologists and dialysis facility partners that also seek to encourage home dialysis and preemptive transplantation through increased risk sharing, effective January 1, 2022. CMS has also solicited suggestions regarding other potential care models. In 2016, CMS initiated the Oncology Care Model demonstration, which provides participating physician practices with performance-based financial incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care, that has been extended by one year (to 2022) due to COVID-19. We believe the Oncology Care Model has reduced utilization of certain of our oncology products by participating physician practices and expect it to continue to do so in the future. Additionally, in late 2019, CMS announced a request for information on the Oncology Care First model, a new voluntary model that builds on the Oncology Care Model. CMS has indicated a continued interest in exploring demonstrations of mandatory models, and may propose both new mandatory payment models in the future that could adversely affect our business. For example, HHS’s September 2021 comprehensive plan to address drug pricing included potential future mandatory models that link payment for prescription drugs and biologics to factors such as: improved patient outcomes, reductions in health disparities, patient affordability, and lower overall costs; bundled payment models; total cost of care models; models in which Medicare Part B savings from utilization of biosimilars, generics, or other high-value products are shared between prescribing providers and the government; models that provide additional Medicare Part D cost-sharing support for biosimilars and generics; and potential expansion of the Part D Senior Savings Model to additional classes of drugs. CMS recently finalized a rule that, starting January 1, 2023, unless a manufacturer can ensure that the full amount of manufacturer patient assistance programs is passed on to the patient, such amount will be treated as a price reduction that will be taken into account when
reporting our Best Price and/or Average Manufacturer Price. Given the use by PBMs and insurers of copay accumulator adjustment programs to apply such patient assistance for the benefit of such companies and not to defray costs to patients, it could be difficult to impossible for manufacturers to ensure that the full value of such amounts is being passed on to the patient. This new policy, if implemented, would have significant implications for our ability to offer copay assistance programs. In this dynamic environment, particularly in light of the pressures on healthcare budgets as a result of the pandemic, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay payment assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.
We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require a biopharmaceutical manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.
The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provisionprovision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can ariseand have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received aan RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. As previously reported, weWe disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. However, weoffice but were unable to reach resolution with the IRS appeals office.resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicativeduplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021 which seek to increase our U.S. taxable income. We firmly believe that the IRS’s positions set forth in the Notices are without merit, and we will vigorously contest the Notices through the judicial process. See Note 4, Income taxes, to the condensed consolidated financial statements.income for 2010-2012.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreedisagreed with the proposed adjustments and calculations and have been pursuingpursued resolution with the IRS administrative appeals office. Asoffice but were unable to reach resolution. In April 2022, we received a consequenceNotice that seeks to increase our U.S. taxable income for 2013-2015 and asserts penalties.
We firmly believe that the IRS positions set forth in the 2010-2012 and 2013-2015 Notices are without merit. We are contesting the 2010-2012 Notices through the judicial process, and we expect to file a Petition in the U.S. Tax Court to contest the 2013-2015 Notice through the judicial process. We will seek consolidation of the 2010-2012two periods into one case in Tax Court litigation, the IRS administrative appeals office recently informed us that it does not plan to engage in discussions at this time regarding the allocation of profits between our entities in the United States and the U.S. territory of Puerto Rico for the 2013-2015 period. Court.
We are also currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination2018 and by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations.
See Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations, Income Taxes; Part I—Note 4, Income taxes, to the Condensed Consolidated Financial Statements.
Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The Tax Cuts and Jobs Act (the 2017 Tax Act) is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The Administration proposed and Congress areis considering significant changes to existing tax law, including an increase in the corporate tax
rate and the tax rate on foreign earnings.law. These changes, if enacted, could substantially increase U.S. taxation of our operations both in and outside the United States, includingtaxes we pay to the U.S. territory of Puerto Rico.government. Further, the OECD recently reached agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, this agreement could result in tax increases in both the United States and foreign jurisdictions. jurisdictions.
The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning 2023, which will increase our U.S. tax liability. The U.S. territory of Puerto Rico is considering changes to its tax system that may minimize or eliminate this impact, but the outcome of such potential changes is uncertain. Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, that would likelyincluding the potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.
| | | | | |
Item 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
During the three months ended September 30, 2021,March 31, 2022, we had one outstanding stock repurchase program, under which the repurchase activity was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Period | | Total number of shares purchased | | Average price paid per share (1) | | Total number of shares purchased as part of publicly announced program | | Maximum dollar value that may yet be purchased under the program(2) |
July 1 - 31 | | 1,763,784 | | | $ | 245.52 | | | 1,763,784 | | | $ | 3,486,312,736 | |
August 1 - 31 | | 1,250,282 | | | $ | 226.31 | | | 1,250,282 | | | $ | 3,203,364,954 | |
September 1 - 30 | | 1,624,898 | | | $ | 217.23 | | | 1,624,898 | | | $ | 2,850,385,563 | |
Total | | 4,638,964 | | | $ | 230.43 | | | 4,638,964 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Period | | Total number of shares purchased | | Average price paid per share (1) | | Total number of shares purchased as part of publicly announced program | | Maximum dollar value that may yet be purchased under the program |
January 1 - 31 | | 1,083,500 | | | 227.99 | | | 1,083,500 | | | 10,642,348,215 | |
February 1 - 28 | | | | | | | | |
Other repurchases | | 280,000 | | | 225.30 | | | 280,000 | | | 10,579,263,848 | |
Accelerated stock repurchases(2) | | 23,258,997 | | | | | 23,258,997 | | | 4,579,263,848 | |
March 1 - 31 | | — | | | | | — | | | 4,579,263,848 | |
Total | | 24,622,497 | | | | | 24,622,497 | | | |
___________
(1) Average price paid per share includes related expenses.
(2) In March 2021, our BoardAs part of Directors increased the amount authorized under our stock repurchase program, the Company entered into ASR agreements with three third-party financial institutions (Dealers) in February 2022. Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion to the Dealers and received and retired an initial 23,258,997 shares of common stock. Approximately $0.9 billion of shares of the Company’s common stock remains to be delivered by anthe Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company’s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional $3.4 billion. In October 2021,shares of common stock to the BoardCompany, or under certain circumstances, the Company may be required to deliver shares of Directors increasedcommon stock or to make a cash payment, at its election, to the amount authorized under our stock repurchase program by an additional $4.5 billion.Dealers.
Reference is made to the Index to Exhibits included herein.
INDEX TO EXHIBITS
| | | | | | | | |
Exhibit No. | | Description |
2.1 | | |
| | |
2.2 | | |
| | |
2.3 | | |
| | |
2.4 | | |
| | |
2.5 | | |
| | |
2.6 | | |
| | |
2.7* | | Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis AdvisorsAdvisors LLC. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential).(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.) |
| | |
3.1 | | |
| | |
3.2 | | |
| | |
4.1 | | |
| | |
4.2 | | Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.) |
| | |
4.3 | | |
| | |
4.4 | | |
| | |
4.5 | | |
| | |
4.6 | | |
| | |
4.7 | | |
| | |
4.8 | | |
| | |
4.9 | | |
| | |
4.10 | | |
| | |
| | | | | | | | |
Exhibit No. | | Description |
4.12 | | |
| | |
4.13 | | |
| | |
4.14 | | |
| | |
4.15 | | |
| | |
4.16 | | |
| | |
4.17 | | |
| | |
4.18 | | |
| | |
4.19 | | |
| | |
4.20 | | |
| | |
4.21 | | |
| | |
4.22 | | |
| | |
4.23 | | |
| | |
4.24 | | |
| | |
4.25 | | |
| | |
4.26 | | |
| | |
4.27 | | |
| | |
4.28 | | |
| | |
4.294.28 | | |
| | |
| | | | | | | | |
4.31Exhibit No. | | Description |
4.30 | | |
| | |
4.324.31 | | Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank & Co., LLC, as co-dealer managers. (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) |
| | |
4.32 | | |
| | |
4.33 | | |
| | |
10.1+ | | |
| | |
10.2+ | | |
| | |
10.3+ | | |
| | |
10.4+ | | |
| | |
10.5+ | | |
| | |
10.6+ | | |
| | |
10.7+ | | |
| | |
10.8+ | | |
| | |
10.9+ | | |
| | |
10.10+ | | |
| | |
10.11+ | | |
| | |
10.12+ | | |
| | |
10.13+ | | |
| | | | | | | | |
Exhibit No. | | Description |
| | |
10.14+ | | |
| | |
10.15+ | | |
| | |
10.16+ | | |
| | | | | | | | |
| | |
10.16+10.17+* | | Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January 1, 2009.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2008 on November 7, 2008 and incorporated herein by reference.) |
| | |
10.17+ | | |
| | |
10.18+ | | |
| | |
10.19+ | | |
| | |
10.20+10.19+ | | |
| | |
10.21+10.20+ | | |
| | |
10.22+10.21+ | | |
| | |
10.23+10.22+ | | |
| | |
10.23+ | | |
| | |
10.24 | | Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent. (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.) |
| | |
10.25 | | |
| | |
10.26 | | |
| | |
10.27 | | |
| | |
10.28 | | |
| | |
10.29 | | |
| | |
| | | | | | | | |
Exhibit No. | | Description |
10.30 | | |
| | |
10.31 | | |
| | |
| | | | | | | | |
10.32 | | |
| | |
10.33 | | |
| | |
10.34 | | |
| | |
10.35 | | |
| | |
10.36 | | |
| | |
10.37 | | |
| | |
10.38 | | |
| | |
10.39 | | |
| | |
10.40 | | |
| | |
10.41 | | |
| | |
10.42 | | |
| | |
10.43 | | |
| | |
10.44 | | |
| | | | | | | | |
Exhibit No. | | Description |
| | |
10.45 | | |
| | |
10.46 | | |
| | |
| | | | | | | | |
10.47 | | Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.) |
| | |
10.48 | | |
| | |
10.49 | | |
| | |
10.50 | | |
| | |
10.51 | | reference.) |
| | |
31* | | |
| | |
32** | | |
| | |
101.INS | | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. |
| | |
101.SCH* | | Inline XBRL Taxonomy Extension Schema Document. |
| | |
101.CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| | |
101.DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| | |
101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| | |
101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| | |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
____________________________
(* = filed herewith)
(** = furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)
(+ = management contract or compensatory plan or arrangement)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | | | | | | | |
| | Amgen Inc. |
| | (Registrant) |
| | | |
Date: | November 2, 2021April 27, 2022 | By: | | /S/ PETER H. GRIFFITH |
| | | | Peter H. Griffith |
| | | | Executive Vice President and Chief Financial Officer |
| | | | (Principal Financial Officer) |